[COMPANY_001] Institutes for BioMedical Research
AIN457 / Secuk inumab
Clinical Trial Protocol C AIN457X2201
A randomized, double- blind , placebo -controlled, 
parallel group ,Phase II, 24-week study  investigating the 
efficac y, safety  and tolerability  of AIN457 in patients with 
active overuse tendinopathy  refractor y to oral 
NSAIDs/acetaminophen , phy siotherapy or 
corticosteroid injections
Document type: Amended Protocol Version
EUDRACT number: 2017 -003099 -30
Version number: v02Clean (incorporating Amendment 02 )
Clinical Trial Phase: II
Release date: 13-Mar-2018
Property of [COMPANY_001]
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of [COMPANY_001]
[COMPANY_001] Confidential Page 2
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  conduct. Note: The SOM will not form part of the Clinical Study Report.
Notification of serious adverse events
Dear Investigator,
You must report a serious adverse event (SAE) (initial or follow -up) to [COMPANY_001] as 
summarized below. Refer to Section 9.2 of the Clinical Trial Protocol for SAE criteria and 
additional requirements. S ee also page 2 of the Site Operations Manual for further details on 
the method of reporting a SAE.
Complete SAE report 
Submit SAE report to [COMPANY_001] Chief Medical Office and Patient Safet y (CMO& 
PS) within 24 hours after awareness of the SAE 
Notify  the [COMPANY_001] Medical Lead
The fax number(s) and email addresses are located in the Site Operations Manual. 
[COMPANY_001] Confidential Page 3
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Table of contents
Site Operations Manual (SOM)................................ ................................ ........................... [ADDRESS_279967] of abbreviations ................................ ................................ ................................ ............ 8
Pharmacokinetic definitions and sy mbols ................................ ................................ ......... 11
Glossary  of terms ................................ ................................ ................................ ............... 12
Amendment 2 (March 2018) ................................ ................................ ............................. 14
Amendment 1 (October 2017) ................................ ................................ ........................... 15
Protocol summary ................................ ................................ ................................ .............. 16
1Introduction ................................ ................................ ................................ ....................... 21
1.1 Background ................................ ................................ ................................ ............ 21
1.2 Nonclinical safety  data ................................ ................................ .......................... 23
1.3 Clinical data ................................ ................................ ................................ ........... 23
1.3.1 Human safet y and tolerability  data ................................ ....................... 23
1.3.2 Human pharmacokinetic data................................................................ 24
1.4 Study  purpose ................................ ................................ ................................ ........ 24
2 Objectives and endpoints................................ ................................ ................................ ...25
2.1 Primary  objective(s) ................................ ................................ ............................... 25
2.2 Secondary  objective(s) ................................ ................................ ........................... 25
2.3 Exploratory  objective(s) ................................ ................................ ........................ 26
3Investigational plan ................................ ................................ ................................ ........... 27
3.1 Study  design ................................ ................................ ................................ ........... 27
3.2 Rationale for stud y design ................................ ................................ ..................... 28
3.3 Rationale for dose/regimen, route of administration and duration of treatment.... 30
3.4 Rationale for choice of comparator ................................ ................................ .......31
3.5 Rationale for choice of background therap y................................ .......................... 31
3.6 Purpose and timing of interim anal yses/design adaptations ................................ ..32
3.7 Risks and benefits ................................ ................................ ................................ ..32
3.7.1 Blood sample volumes ................................ ................................ .......... 33
4Population ................................ ................................ ................................ .......................... 34
4.1 Inclusion criteria ................................ ................................ ................................ ....34
4.2 Exclusion criteria ................................ ................................ ................................ ...35
5 R estrictions for study subjects ................................ ................................ ........................... 39
[COMPANY_001] Confidential Page 4
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
5.1 Prohibited treatment ................................ ................................ ............................... 39
6Treatment ................................ ................................ ................................ ........................... 40
6.1 Study  treatment ................................ ................................ ................................ ......40
6.1.1 Investigational and control drug(s) ................................ ....................... [ADDRESS_279968] to follow -up ................................ ................................ ................................ ...48
7.5 Early study termination by [CONTACT_456] ................................ ................................ .48
8 Procedures and assessments ................................ ................................ .............................. 49
8.1 Assessment schedule ................................ ................................ ............................. 49
8.2 Informed consent procedures................................................................................. 52
8.3 Patient screening................................ ................................ ................................ ....53
8.4 Information to be collected on screening failures ................................ .................. 53
8.5 Patient demographics/other baseline characteristics ................................ ............. [ADDRESS_279969], drug screen ................................ ................................ .......54
8.5.3 X- ray of the shoulder ................................ ................................ ............ 54
8.5.4 Treatment exposure and compliance ................................ ..................... 54
8.6 Efficacy ................................ ................................ ................................ .................. 54
8.6.1 The PRO efficacy  measures, primary  and secondary  objectives: ......... 54
8.6.2 Clinician reported outcome (CRO) efficacy  measures collected in 
the trial for secondary  objectives ................................ .......................... 57
[COMPANY_001] Confidential Page 5
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
8.6.3 Imaging efficacy  measures collected in the tr ial for secondary  and 
exploratory  objectives are: .................................................................... [ADDRESS_279970] X -ray........................................................................................... 61
8.7.8 Tolerability  of investigational treatments ............................................. 61
8.7.9 Laboratory  evaluations .......................................................................... 61
8.7.10 Pregnancy  and assessments of fertility ................................................. 62
8.7.11 Additional parameters ........................................................................... 63
8.8 Pharmacokinetic s
................................................................................................... 63
8.9 Other assessments .................................................................................................. 64
8.9.3 Immunogenicity .................................................................................... 64
9Safet y monitoring .............................................................................................................. 66
9.1 Adverse events ....................................................................................................... 66
9.2 Serious adverse event reporting ............................................................................. 67
9.2.1 Definition of SAE ................................................................................. 67
9.2.2 SAE reporting
........................................................................................ 68
9.3 Liver safety  monitoring ......................................................................................... 69
9.4 Renal safet y monitoring ......................................................................................... 70
9.5 Reporting of stud y treatment errors including misuse/abuse ................................ 70
9.6 Pregnancy  reporting ............................................................................................... 71
10Data review and database management ............................................................................. 71
10.1 Site monitoring ...................................................................................................... 71
10.2
Data collection....................................................................................................... 72
10.3 Database management and quality  cont rol............................................................ 72
10.4 Data Monitoring Committee .................................................................................. 73
10.5
Adjudication committee......................................................................................... 73
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 6
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
11Data analy sis................................ ................................ ................................ ...................... [ADDRESS_279971] demographics and other baseline characteristics...................................... 74
11.3 Treatments ............................................................................................................. 74
11.4 Analy sis of the primary  variable(s) ....................................................................... 74
11.4.1 Primary  Variable(s) ............................................................................... 74
11.4.2 Statistical model, hy pothesis, and method of analysis .......................... 74
11.4.3 Handling of missing values/censoring/discontinuations ....................... 74
11.4.4 Summary  statistics of safety
.................................................................. 75
11.4.5 Sensitivity analyses............................................................................... 75
11.5 Analy sis of secondary  variable(s) .......................................................................... 75
11.5.1 Efficacy  / Pharmacod ynamics ............................................................... 76
11.5.2 Safet y
..................................................................................................... 76
11.5.3 Pharmacokinetics .................................................................................. 76
11.5.4 Pharmacokinetic / pharmacod ynamic correlation analysis ................... 76
11.5.5 Other assessments ................................................................................. 77
11.6 Analy sis of exploratory  variables
.......................................................................... 77
11.7
Sample size calculation.......................................................................................... 77
11.8 Power for anal ysisof key secondary  variables ...................................................... 77
11.9 Interim anal yses..................................................................................................... 78
12Ethical co
nsiderations ........................................................................................................ 78
12.1 Regulatory
 and ethical compliance ........................................................................ 78
12.2 Responsibilities of the investigator and IRB/IEC .................................................. 78
12.3 Publication of study  protocol and results ............................................................... 79
12.4 Quality  control and quality  assurance .................................................................... 79
13Protocol adherence ............................................................................................................ 79
13.1 Protocol amendments ............................................................................................. 79
14References ................................ ................................ ................................ ......................... 80
15Appendix 1: Clinically  notable laboratory  values and vital signs ..................................... 83
Commercially Confidential Information
[COMPANY_001] Confidential Page 7
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
List of tables
Table 5-1 Prohibited medications................................ ................................ .......... 39
Table 6-1 Overv iew of study  medication ................................ .............................. 40
Table 6-2 Blinding and unblinding plan................................ ................................ 43
Table 8-1 Assessment schedule ................................ ................................ ............. 49
Table 9-1 Guidance for capturing study  treatment errors................................ ......70
Table 15-1 Safety  Anal yses: Expanded L imits and Notable Criteria ...................... [ADDRESS_279972] of figures
Figure 3 -1 Study  design ................................ ................................ .......................... 28
[COMPANY_001] Confidential Page 8
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
List of abbreviations
AE Adverse event
ALT Alanine aminotransferase
ALP Alkaline phosphatase
anti-CCP Anti- cyclic citrullinated peptide 
AP Anterior -posterior
AS Anky losing spondylitis
ASES American s houlder and elbow s urgeons shoulder score
AST Aspartate aminotransferase
BUN B
lood urea nitrogen
CK Creatinine kinase
CMO &PS Chief Medical Office & p atient safety
CRF Case report/record f orm (paper or electronic)
CRO Contract research o rganization
CSR Clinical study  report
CT Computerized tomography
CTC Common toxicity  criteria
CV Coefficient of variation
ECG Electrocardiogram
EDC Electronic data c apture
ELISA Enzy me-linked immunosorbent assay
EoS End of the Study
eSource Electronic source
EQ5D EuroQol -5D
EU Europe
FDA Food and Drug Administration
GCP Good Clinical Practice
GGT Gamma -glutam yl transferase
h Hour
HAQ- DI Health assessment questionnaire disability  index
Commercially Confidential Info rmation
[COMPANY_001] Confidential Page 9
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
hCG Human chorionic gonadotropin
HCV Hepatitis C virus
HIV Human immunodeficiency virus
IB Investigators brochure
ICF Informed consent f orm
ICH International Conference on Harmonization of Technical Requirements for 
Registrati on of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IGA Investigator’s global a ssessment
IL Interleukin
IL-17/IL -17A Interleukin [ADDRESS_279973]
MedDRA Medical dictionary  for regulatory  activities 
Sv MicroSievert
mSv MilliSievert
MRI Magnetic resonance i maging
NSAIDs Non- steroidal anti -inflammatory  drugs
PASI Psoriasis area and severity i ndex
PCR Polymerase c hain reaction
PD Pharmaco -dynamic(s)
PFS Prefilled sy ringe
PGA Patient global assessment
PhGA Physician global assessment
PK Pharmacokinetic(s)
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential In formation
[COMPANY_001] Confidential Page 10
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
[COMPANY_003] Purified protein derivative
PRO Patient reported o utcome
PRP Platelet rich plasma
PsA Psoriatic a rthritis
RA Rheumatoid arthritis
RBC Red blood cell(s)
RC Rotator c uff
RF Rheumatoid factor 
RNA Ribonucleic acid
SAE Serious adverse event
s.c. Subcutaneous
sCR Serum creatinine
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic p yruvic transaminase
SD Standard deviation
SOM Site operations m anual
SpA Spondy larthritides
S[LOCATION_003]R Suspected unexpected serious adverse r eactions
TB Tuberculosis
TBL Total bilirubin
Tmax Time to maximum concentration
TNF Tumor necrosis factor -α inhibitor
TNF -IR Tumor necrosis factor -α inhibitor incomplete responders
ULN Upper limit of normal
VAS Visual analog scale
WBC White blood cell(s)
WHO World health o rganization
WoC Withdrawal of c onsent
WORC Western O ntario rotator c uff(score)
Commercially Confidential Information
Commercially Confidential Information
Commercially Conf idential Information
[COMPANY_001] Confidential Page 11
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Pharmacokinetic definitions and sy mbols
Cmin The lowest serum concentration observed during a dosing interval [mass / 
volume]
[COMPANY_001] Confidential Page 12
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Glossary  of terms
Assessment A procedure used to generate data required by  [CONTACT_37214] A specific group of subjects fulfilling certain criteria
Control drug Any drug(s) (an active drug or an inactive drug, such as a 
placebo) which is used as a comparator to the investigational 
drug being tested in the trial
Dosage Dose of the study  treatment given to the subject in a time unit 
(e.g. 100 mg once a day , 75 mg twice a day )
Electronic data c apture 
(EDC)Electronic data capture (EDC) is the electronic acquisition of 
clinical study  data using data collection systems, such as Web -
based applications, interactive voice response systems and 
clinical laboratory  interfaces.
EDC includes the use of Electronic Case Report Forms (eCRFs) 
which are used to capture data transcribed from paper source 
forms used at the point of care.
Enrollment Point/time of subject entry  into the study  at which informed 
consent must be obtained (i.e. prior to starting any of the 
procedures described in the protocol)
Epoch Interval of time in the planned conduct of a study .An epoch is 
associated with a purpose (e.g. screening, randomization, 
treatment, follow -up) which applies across all arms of a study .
eSource eSource Direct Data Entry  (DDE) refers to the capture of 
clinical study  data electronically , at the point of care. eSource 
combines source documents and case report forms (eCRFs) into 
one application, allowing for the real time collection of clinical 
trial information to sponsors and other oversight authorities, as 
appropriate.
Investigational drug The study  drug whose properties are being tested in the study ; 
this definition is consistent with US CFR 21 Section 312.3 and 
Directive 2001/20/EC and is synony mous with “investigational 
new drug,” "Investigational Medicinal Product," or “test 
substance”
Medication pack number A unique identifier on the label of each drug package in studies 
that dispense study  treatment using an IRT s ystem
Patient An individual with the condition of interest
[COMPANY_001] Confidential Page 13
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Randomization number A unique identifier assigned to each randomized subject, 
corresponding to a specific treatment arm assignment
Run in f ailure A subject who is screened but not randomized/treated after the 
run-in period (where run-in period requires adjustment to 
subject’s medications or other intervention) 
Screen f ailure A subject who is screened but is not treated or randomized 
Subject A trial participant (can be a healthy  volunteer or a patient)
Subject number A unique number assigned to each subject upon signing the 
informed consent. This number is the definitive, unique
identifier for the subject and should be used to identify  the 
subject throughout the study  for all data collected, sample 
labels, etc.
Source Data/Document Source data refers to the initial record, document, or primary  
location from where data comes. The data source can be a 
database, a dataset, a spreadsheet or even hard-coded data, such 
as paper or eSource.
Study  treatment Any drug or combination of drugs administered to the study  
participants as part of the required study  procedures; includes 
investigational drug(s), control(s) or background therapy  
Study  treatment 
discontinuationWhen the subject permanently  stops taking study  treatment prior 
to the defined stud y treatment completion date
Variable A measured value or assessed response that is determined in 
specific assessments and used in data analysis to evaluate the 
drug being tested in the study  
Withdrawal of consent 
(WoC)Withdrawal of consent from the study  is defined as when a 
subject does not want to participate in the study  any longer, and
does not want any further visits or assessments, anddoes not 
want any further study related contact, and does not allow 
analysis of alread y obtained biologic material
[COMPANY_001] Confidential Page 14
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 15
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Commercially Confidential Information
[COMPANY_001] Confidential Page 16
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Protocol summary
Proto col number CAIN457X2201
Full Title A randomized, double -blind, placebo -controlled, parallel group, Phase II, 
24-week study  investigating the efficacy , safety  and tolerability of AIN457 in
patients with active overuse tendinopathy refractory to oral
NSAIDs/acetaminophen, physiotherapy or cortico steroid injections
Brief title Study of efficacy , safety and tolerability of AIN457 in patients with active 
overuse tendinopathy
Sponsor and Clinical 
Trial Phase[COMPANY_001] 
Phase II
Intervention type Biologic
Study type Interventional 
Purpose and 
rationaleCosenty x is an anti-IL-17 antibody, approved for the treatment of PsA and 
AS, and there is a plenitude of evidence of efficacy  in treating the enthesitis 
in patients with these s ymptoms in both these indications.
Recent musculoskeletal scientific attention has focused on the 
immunobiology of the enthesis, the connective tissue between tendon or 
ligament and bone. This area has been considered analogous to 
tendinopathy as both enthesis and tendon are sites of high mechanical 
stress.
Millar et al (2017) has provided recent evidence indicating that 
IL-17-expressing tendon -resident immune cells are present in human overuse 
tendinopathy and IL -17 mR NA and protein expression levels are increased in 
early human tendinopathic samples. IL-17, being a mediator of tendon 
inflammation, disrepair of tendon matrix and tenocy te apoptosis is thus 
considered to be a key player in the patho genesis of overuse tendinopathy. 
The study design addresses the primary objective of determining the efficac y 
of secukinumab in improving signs, symptoms and structure in patients with 
overuse rotator cuff tendinopathy. 
Primary Objective(s) To assess the efficacy  of secukinumab 300 mg s.c. vs. placebo in patients 
with overuse rotator cuff tendinopathy  in relieving clinical symptoms at week 
14
Secondary 
ObjectivesTo assess the efficacy  of secukinumab 300 mg s.c. vs. placebo in patients 
with overuse rotator cuff tendinopathy in relieving s ymptoms over time
To assess the structural changes in the rotator cuff tendinopathy over time
To assess PK/immunogenicity in secukinumab treated patients
To confirm the safety and tolerability of AIN457 in overuse rotator cuff 
tendinopathy over time
[COMPANY_001] Confidential Page 17
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Study design This is a randomized, double -blind, placebo -controlled, multi-center, Phase II 
study of s.c. secukinumab 300 mg in approximately 100 randomized patients 
with overuse rotator -cuff tendinopathy without systemic inflammatory disease 
and refractory to NSAIDs/acetaminophen, physioth erapy or corticosteroids. 
The patient and investigator will be blinded throughout the study , while the 
sponsor will be blinded until after the analysis of the primary  endpoint. 
Thestudy consists of a 4-week screening period, a 2-week run-in period, a 
12-w eek treatment period and a [ADDRESS_279974] treatment
(Figure 3 -1).
The population will consist of patients with MRI- positive unilateral overuse 
(non-systemic inflammatory) shoulder te ndinopathy, 18 -65 years of age. 
The screening period will be used to assess eligibility and to start/continue 
patients on physiotherapy. In the run-in period the patient should have 
2weeks of stable NSAID/acetaminophen intake and standardized 
physiothe rapy (defined in the SOM). Patients who meet the eligibility criteria 
at screening after the run -in period will go through baseline evaluations.
Eligible subjects as per inclusion/exclusion criteria will be randomized to one 
of the two treatment arms: 7 s.c. injections of secukinumab 300 mg or 
placebo in a 12-week treatment period, followed by a 12-week follow -up 
period. Randomization will be stratified by [CONTACT_716] 2 factors: 
Partial tear/no tear and previous steroid injection ( yes/no), in order to ach ieve 
approximate balance between these factors in the treatment groups. 
Theassessments to address the primary endpoint will be performed at 
14weeks ([ADDRESS_279975] injection).
Patients will come to the out-patient clinic approximately 2-4 hours prior to 
dosing for the evaluations. Dosing will be on-site, except for injections at 1 
and 3 weeks, that can be done either on site or by a nurse at the patient’s 
home. 
Safety assessments will include physical examinations, ECGs, vital signs, 
standard clinical laboratory evaluations (hematology, blood chemistry , and 
urinalysis), adverse event and serious adverse event monitoring.
Population The population will consist of male and female patients at least 18 years of 
age, but under or equal to 65 years of age at the time point of randomization 
with a MRI-positive diagnosis of overuse (non-systemic inflammatory ) 
unilateral shoulder tendinopathy with symptoms present for at least 6 weeks 
but not more than 12 months.
[COMPANY_001] Confidential Page 18
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Key Inclusion 
criteriaPatients eligible for inclusion in this study  must fulfill all of the following 
criteria:
Written informed consent obtained prior to all study specific screening
procedures, as close to the start of the screening period as possible
Male or non -pregnant, non -lactating female patients 18 to 65 years of
age at randomization
Presence of unilateral rotator cuff tendinopathy with:
a.Symptoms present ≥6 weeks, but <12 months prior to randomization
b.Tendinopathy with no more than a 50% tear as established by
[CONTACT_232107]: Sein MRI tendinopathy
scoring system grade I -III; with no tear or partial tear [maximum 50%
tendon thickness (Bauer tendon thickness score maximum 2);
APlength maximum 10 mm (Bauer tendon length score max 2)].
Maximum 50% of patients with partial tear
c.Pain in the affected shoulder (at rest or on movement) on at least
3days out of [ADDRESS_279976] week prior to baseline and a score of
≥4 out of 10 on a VAS pain scale
d.Positive “Painful Arc Test” on examination and/or nightly pain in the
affected shoulder on at least [ADDRESS_279977] week prior to
baseline
The rotator -cuff tendinopathy must have been refractory to standard
treatment defined as:
NSAIDs / acetaminophen
In the run -in period patients shoul d be on a stable dose of
NSAIDs and/or acetaminophen for at least 2 weeks prior to
randomization, not exceeding –e.g.: Ibuprofen 1600 mg/d,
naproxen 1000 mg, diclofenac 105 mg/d, or diclofenac sodium
enteric -coated tablets 150 mg/d, or equivalent.
If pat ientscannot tolerate these doses, the maximal tolerable
dose should be used, and may be augmented with
acetaminophen/paracetamol, at doses not exceed local
guidelines or 4 g/day, whichever is lower. This medication should
also be at a stable dose for at l east 2 weeks.
If patients have contraindications to NSAIDs or to
acetaminophen, these treatments can be omitted
(contraindication, drug and dose must be specified in the eCRF).
If patients were refractory to at least 2 weeks of previous
treatment as specified in 4 i/ii, NSAIDs or acetaminophen
treatment can be omitted.
Physiotherapy
In the run in period p atients should have had [ADDRESS_279978] 6 week s of
physiotherapy prior to randomization. This includes the 2 weeks
of standardized physiotherapy in run in phase.
[COMPANY_001] Confidential Page 19
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Key Exclusion 
criteriaHistory of hypersensitivity to any of the study treatments or excipi[INVESTIGATOR_232086]
Rheumatologic, inflammatory diseases, including but not limited to: PsA,
AS and RA
Previous shoulder surgery in affected shoulder
History of adhesive capsulitis/frozen shoulder or calcification in the
tendon (in affected or contralateral shoulder) confirmed by X -Ray, historic
X-Rays can be used if performed within 3 months of baseline
Symptomatic osteoarthritis of the shoulder (gleno -humeral,
acromiocla vicular) (in affected or contralateral shoulder confirmed by
X-Ray, historic X -Rays can be used if performed within 3 months of
baseline
Neck conditions, including but not limited to cervical spi[INVESTIGATOR_232087],
which in the opi[INVESTIGATOR_871], may explain the patient’s
symptoms
Previous platelet rich plasma injections within the last 12 months prior to
randomization
Study treatmentGroup 1: Secukinumab 300 mg s.c. (2 x 150 mg)
Group 2: Placebo s.c. (2 injections)
Pharmacokinetic 
assessmentsPK/immunogenicity assessment
Efficacy/PD 
assessmentsPatient Reported Outcomes (PROs)
The WORC score
The QuickDASH score
The ASES score
The EQ5D- 5L score
Patient’s global asse ssment of disease activity
Clinician Reported outcome
Physician’s global assessment of disease activity
Imaging
Shoulder MRI
Key safety 
assessmentsKey safety assessments:
Evaluation of AE/ SAE’s
Physical examination
Vital signs
Height and weight
Tuberculosis screening: QuantiFERON TB -Gold test or [COMPANY_003] skin test
Chest X -Ray
Electrocardiogram
Local tolerability (Injection site reactions)
Laboratory evaluations (Hematology, Clinical Chemistry, Lipid Panel,
Urinalysis)
Pregnancy and assessm ent of fertility
Immunogenicity
Commercially Confidential Information
Commer cially Confidential Information
[COMPANY_001] Confidential Page 20
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Other assessments
Data analysis The primary end-point (change from baseline in WORC score at Week 14) 
will be analyzed by [CONTACT_232108]. Change at Week 14 will be compa red between 
treatments to address the primary  objective. The baseline WORC score will 
be included as a covariate. The stratification factors partial tear/no tear and 
previous steroid injection (yes/no) will be included in the model as fixed 
effects. A 95% one-sided (90% two-sided) confidence interval for the 
treatment effect at Week [ADDRESS_279979] covariance and a 
separate mean for each treatm ent and time point will be fitted. These models 
may be reduced in number of covariance and mean parameters by [CONTACT_232109].
Key words Overuse tendinopathy, shoulder, rotator cuff , IL-17A-Ab
Commercially Confidential Information
[COMPANY_001] Confidential Page 21
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
1 Introduction
1.1 Background
Overuse tendinopath y is a complex multi- faceted disease of the tendon, clinically  diagnosed 
after gradual onset of activity -related pain, decreased function and sometimes with localized 
swelling of the tendon (Riley  2 005, Riley  2 008). Historically  the terms ‘tendinitis’ and 
‘tendinosis’ have i nterchanged with the term ‘tendinopathy ’, however, these definitions are 
now included in the spectrum of human tendon disorders (‘tendinopathy ’). Tendinopath y isa 
common overuse injury  in the athletic and working populations; it is the most common reason 
for consultation for a musculoskeletal complaint, corresponding to around 30% of all such 
consultations with a general practitioner ( Forde et al 2005; Riley  2008).
The exact incidence of overuse tendon injuries is not known, but in sports medicine, they 
account for 30 %to 50% of all injuries (Scott and Ashe 2006 ). Generally , for phy sical workers, 
the prevalence of musculoskeletal symptoms increases with duration of employ ment 
(Forde et al 2005 ).
Upper limb tendinopathy
A systematic review showed that the incidence of rotator cuff tendinopathy  ranges from 0.3% 
to 5.5% per year and the annual prevalence from 0.5% to 7.4% (Littlewood et al2013 ). 
Theincidence is higher inphysical workers and athletes (15-20%) and i n the wheelchair 
populations (31-73%). It is typi[INVESTIGATOR_1306] y seen in swimmers, baseball -, tennis-, volley ball players
(Kaux et al 2011).
Tennis elbow (lateral epi[INVESTIGATOR_232088]) is another frequent tendinopath y and is common in 
athletes of all ages participating in sports involving overhead or repetitive arm actions 
(Hume et al 2006 ). Its incidence in te nnis players is as high as 9 %to 40% (Maffulli et al 2003 ; 
Scott and Ashe 2006 ). The condition affects approximately  1 to 3% of the general population. 
Another e lbow tendinopathy  is the golfer’s elbow (medial epi[INVESTIGATOR_232089]), which is a typi[INVESTIGATOR_232090], baseball and golf (Maffulli et al 2003 ; Scott and Ashe 2006). 
Lowerlimb tendinopathy
Achilles tendinopath y is the most prevalent lower extremity  tendinopathy , with a 
5.9% frequency  in sedentary  people and around a 50% frequency  in elite endurance athletes 
(Scott and Ashe 2006; Fredberg and Stengaard -Pedersen 2008 ).
About one third of sports injuries treated in sports clinics concern the knees and one quarter of 
athletes treated for a knee injury are diagnosed with tendinopathy  (Maffulli e t al 2003 ). Themost 
common knee disorder is jumper’s knee (insertional patellar tendonitis) , and its incidence is reported 
to be in the range of 7 % to 40% (Fredberg and Stengaard-Pedersen 2008; Scott and Ashe 2006). 
[COMPANY_001] Confidential Page 22
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Treatments
Current treatments for tendinopathy  arerest, icepacks and physiotherap y (including 
therapeutic ultrasound, laser therapy , hyperthermia and extra corpor eal shockwave therapy ). 
Evidence to support the widespread use of these therapi[INVESTIGATOR_232091] (Alfredson and Cook 2007 ). Non-steroidal anti-inflammatory  drugs (NSAIDS ), 
or local corticosteroid i njections can give transient pain relief, but the long term benefit is 
questionable ( Mohamadi et al 2017; Coombes et al 2010). Even more, it has been shown that 
repetitive steroid injections have the potential to accelerate tendon degeneration increasing the 
risk of tendon rupture (Mohamadi et al 2017 ; Coombes et al 2010 ).  Autolo gous platelet rich 
plasma (PRP) i njections are being used, however the evidence for long term efficacy  is weak, 
thus the benefits of PRP for tendinopathy  remain controversial, with several trials showing no 
efficacy  compared with saline ( Krogh et al 2013; de Vos et al 2010 ). 
Overall , overuse tendinopathy  is a disease with high medical need without adequate treatment 
options.
Secukinumab ( AIN457, Cosenty x®), interleukin -17A (IL-17A)neutralization
IL-17A is a central cy tokine in multiple autoimmune and inflammatory  processes. 
Recent evidence indicates that IL-17-expressing tendon- resident immune cells are present in 
human overuse tendinopathy  and IL-17 mRNA and protein expres sion levels are increased in 
early human tendinopathic samples. In human tenocy tes, IL-17 regulates pro-inflammator y 
cytokines, key apoptotic mediators and tendon matrix changes towards a mechanically 
inferior t ype III collagen phenoty pe. IL -17 being a med iator of tendon inflammation, disrepair 
of tendon matrix and tenocy te apoptosis is thus considered to be a key player in the 
pathogenesis of overuse tendinopathy  (Millar et al 2017 ).
Secukinumab is a selective high-affinity  fully human monoclonal antibody  that neutralizes 
IL-17A and isapproved in more than 70 countries forthe following indications: 1) Moderate 
to severe plaque psoriasis in adult patients , including postular psoriasis (Japan only ); 2) adults 
with active psoriatic arthritis (PsA) ;3) adults with active ankylosing spondy litis (AS) 
(Cosenty x  prescribing information 2016 ). 
Enthesitis is the term used to describe inflammation at tendon, ligament or joint capsule 
insertions. It applies to diseases associated with the spondy larthritides (SpA) including AS 
and PsA. Enthesitis can be inflammatory  or mechanically  induced; the two may share 
common features (McGonag le and Benj amin 2009). Neutralization of IL-17 has proven 
efficacy  in inflammatory  enthesitis in PsA and AS,as seen in studies with secukinumab: 
CAIN457F - 2305, 2306, 2310, and 2312. In study  CAIN457F2312, enthesitis was evaluated 
in the subset of patients who had disease activity  at baseline. In this patient population 
secukinumab significantly  increased the percentage of patients with resolution of enthesitis 
compared with placebo (CAIN457F2312 CSR) . Overall, the percentage of patients without 
resolution of enthesitis at Week 24 was 67.6%, 57.8%, 51.8%, 59.6%, and 78.5% for 
secukinumab 75 mg, 150 mg, 300 mg, secukinumab pooled, and placebo groups, respectivel y. 
These differences vs. placebo were also greater for the 150 mg and 300 mg dose groups vs 
placebo (p=0.0108 and p=0.0025, respectivel y), while 75 mg vswas similar (p=0.1678) to 
placebo . 
[COMPANY_001] Confidential Page 23
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Neutralization of IL-[ADDRESS_279980] relevant data for the present study are summarized in the sections below. 
Fordetailed information, please refer to the Investigator's Brochure or Core Data Sheet.
Data from this study  are aimed at supporting the planning and design of the Phase III studies 
for global submission of secukinumab as a treatment option for patients with active 
tendinopathy .
1.2 Nonclinical safety  data
1.3 Clinical data
1.3.1 Human safety  and tolerability  data
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 24
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
1.3.2 Human pharmacokinetic data
1.4 Stud y purpose
The purpose of this Phase II study  is to determine the efficacy  of secukinumab in treating 
patients with a diagnosis of overuse, non -systemic inflammatory  rotator cuff tendinopathy  and 
to confirm the safet y and tolerability  profile of secukinumab in a dose of 300 mg s.c. given at 
day 1 and weekl y until and including week 4, thereafter additional injections at weeks 8 
and12. 
. Patients will be followed up without treatment from week 
12 to week 24 to 
investigate long- term safety .
Commercially C onfidential Information
Commercially Conf idential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 25
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
2 Objectives and endpoints
2.1 Primary  objective(s)
Objective Endpoint
To assess the efficacy  of secukinumab
300 mg s.c. vs. placebo in patients with
overuse rotator cuff tendinopathy  in
relieving clinical s ymptoms at week 14The Western Ontario Rotator Cuff
(WORC) patient reported outcome (PRO)
score at week 14
2.2 Secondary  objective(s)
Objective Endpoint
To assess the efficacy  of secukinumab
300 mg s.c. vs. placebo in patients with
overuse rotator cuff tendinopathy  in
relieving sy mptoms over timeWORC score at Weeks 2, 4, 8, 12, 18 and 24
Disability  of Arm, Shoulder and Hand
Questionnaire (QuickDASH) score at
Weeks 2, 4, 8, 12, 14, 18 and 24
American Shoulder and Elbow Surgeons
Shoulder Evaluation Form (ASES) score at
Weeks 2, 4, 8, 12, 14, 18 and 24
EQ5D -5Lscore at W eeks 2, 4, 8, 12, 14, 18
and 24
Pain score using a VAS scale (con sidering
the last 24 hours) at W eeks 2, 4, 8, 12, 14, 18
and 24
Patient global assessment (PGA) score using
a VAS scale (cons idering the last 24 hours),
at W eeks 2, 4, 8, 12, 14, 18 and 24
Physician global assessm ent (PhGA) score
using a VAS scale (considering the last
24hours), at W eeks 2, 4, 8, 12, 14, 18 and 24
To assess the structural changes in the
rotator cuff tendinopath y over timeMRI  Sein score at Weeks 8, 14 and 24
To assess PK/immunogenicity  in
secukinumab treated patientsPK/immunogenic ity assessment at Day 1,
Weeks 4, 12, 24
To confirm the safet y and tolerability
of AIN457 in patients with overuse
rotator cuff tendinopath y over timeSafet y and tolerability assessments over
time: Incidence and severity  of AEs and
SAEs; routine safet y laboratory  parameters
[COMPANY_001] Confidential Page 26
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
2.3 Exploratory  objective(s)
Commercially Confidential Information
[COMPANY_001] Confidential Page 27
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
3 Investigational plan
3.1 Stud y design
This is a randomized, double -blind, placebo -controlled, multi- center, Phase II study  of s.c. 
secukinumab 300 mg in approximately  100 randomized patients with overuse rotator -cuff 
tendinopathy  w ithout systemic inflammatory  d isease and refractory  t o 
NSAIDs /acetaminophen , physiotherap y or corticosteroids. The patient and investigator will 
be blinded throughout the study , while the sponsor will be blinded until after the analysis of 
the primary  endpoint. The study  consists of a [ADDRESS_279981] treatment (Figure 3 - 1).
The population will consist of patient swith MRI -positive unilateral overuse (non-systemic 
inflammatory ) shoulder tendinopathy , [ADDRESS_279982] been 
refractory  to NSAIDS/acetaminophen asdefined in the inclusion criteria. On MRI, patients 
may have no tendon tear or a partial tendon tear (up to 50% thickness, in max. 50% of 
patients). The patients should also have had at least 2 weeks of a standardized physiotherap y 
treatment .
The screenin g period will be used to assess eligibility  and to start/continue patients on 
physiotherapy . In the run-in period the patient should have 2 weeks of stable 
NSAID /acetaminophen intake and standardized physiotherapy (defined in the SOM) . 
Patients who meet the eligibility  criteria at screening after the run-in period will go through 
baseline evaluations.
Commercially Confidential Information
[COMPANY_001] Confidential Page 28
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Eligible subjects as per inclusion/exclusion criteria will be randomized to one of the two 
treatment arms: 7 s.c. injections of secukinumab 300 mg or placebo in a 12-week treatment 
period, followed by a  12-week follow -up period. Randomization will be stratif ied by [CONTACT_14504] 2 factors: Partial tear/no tear and previo us steroid injection (yes/no), in order to 
achieve approximate balance between these factors in the treatment groups. The assessments 
to address the primary  endpoint will be performed at 14 weeks ([ADDRESS_279983] 
injection).
Patients will come to the out-patient clinic approximately  2-4 hours prior to dosing for the 
evaluations. Dosing will be on-site, except for injections at 1 and 3 weeks, that can be done
either on site or b y a nurse at the patient’s home. 
Safet y assessments will include physical examinations, ECGs, vital signs, standard clinical 
laboratory  evaluations (hematology , blood chemistry , and urinal ysis), adverse event and 
serious adverse event monitoring.
Figure 3-1 Study  design
3.2 Rationale for study  design
Thestudy design addresses the primary  objective of determining the efficacy  of secukinumab
in improving signs, sy mptoms and structure in patients with overuse rotator cuff tendinopathy. 
The study  will enroll patients with inadequate response (determined by a VAS pain score ≥4) 
to physiotherap y or NSAIDs /acetaminophen or intolerance to NSAIDs /acetaminophen, using 
a double -blinded, randomized, parallel group design to minimize bias. At the time of inclusion, 
patients can be steroid -naïve or have inadequate response or intolerance to local steroid 
injection in the tendon, but last steroid therapy  must have been >[ADDRESS_279984] 
frequent tendinopathies. Moreover, the clinical evidence for an IL-17 connection has so far 
only been shown for rotator cuff tendinopath y and has not been investigated for other 
tendin opathies (Millar et al 2017 ).

[COMPANY_001] Confidential Page 29
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Currently , no Health Authority  guideline exists for developi[INVESTIGATOR_232092]. The 14-week endpoint is chosen to allow the last injection at 
12weeks to take effect.
The stud y uses validated Patient Reported Outcome (PRO) questionnaires including indices of 
signs, symptoms and physical function. The PROs used have been chosen based on their validity, 
reliability  and specificity . The different PROs have different recall times, 1 week, 24 hours, and a 
moment in ti me. One is specific for rotator cuff; two others are for arm and shoulder .
During the 2-week run-in period patients should take NSAIDs /acetaminophen at a stable and 
adequate (or maximally tolerable) dose, and still have inadequate control of symptoms at 
randomization. Alternatively NSAID should have been stopped due to intolerance. 
Patients who tolerate itwill continue taking the NSAID regimen from the run-in period. 
Patients should not increase the NSAID/acetaminophen dose, but can choose to decrease the 
dose at any time. Dose adjustments are allowed after the primary  endpoint at [ADDRESS_279985] on the 
tendinopathy .
The rationale for key  design elements in this study  include:
Randomization: This decreases the chance of an imbalance in subject characteristics between 
groups, thereb y facilitating a valid basis for the treatment comparison.
Double -blind: Blinding of subjects, investigators and sponsor up to the point of week 14, the 
primary  endpoint, allows for an unbiased assessment of subjective readouts such as the 
efficacy  parameters, especiall y the PROs and as well foradverse events evaluation. 
The blinding is maintained for patient and investigator beyond the primary  endpoint until the 
end of the study  to ensure reliable efficacy  and safet y measures. The sponsor will be 
unblinded after the primary  endpoint ana lysis. 
Placebo- controlled: A placebo arm is included in this study  because it is not known whether 
secukinumab can improve tendinopathy , and because there is no disease modify ing therapy 
available. However, standard of care with NSAIDs and physiotherapy will be given to both 
treatment groups throughout the study , andif required a steroid injected into the tendon canbe 
given also in both groups. Due to the nature of the disease and the outcome measures used, a 
placebo arm is necessary  to obtain reliable efficacy  measurements ,to judge the size of the 
active treatment compared to change over time in the placebo group , and to reasonabl y 
attribute adverse events to secukinumab .
[COMPANY_001] Confidential Page 30
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
Phas e III studies in patients with active PsA (CAIN457F2306 and CAIN457F2312) 
demonstrated the superior efficacy  of secukinumab 150 mg s.c. and 300 mg s.c.
(CAIN457F2312 only) regimens over placebo. Secukinumab [ADDRESS_279986] efficacy  across multiple PsA domains in tumor necrosis 
factor -α inhibitor (TNF) incomplete responder (TNF -IR)patients and showed higher efficacy 
on skin endpoints and physical function as measured by[CONTACT_53820] -DI in both TNF -naïve patients 
and TNF -IR patients .
Evidence ofdose response was shown in TNF -IR patients favoring secukinumab 300 mg over 
150 mgat the Week 24 efficacy  endpoint used for the primary  and secondary  efficacy 
analyzes of CAIN457F2312 study. Indeed, ACR20/50/70 response rates at Week 24 in 
TNF -IR patients were higher with secukinumab 300 mg compared to 150 mg (45.5% vs 
29.7%, 27.3% vs 18.9%% and 15.2% vs 10.8% respectivel y). This trend was maintained up to 
Week 52.
Further more , secukinumab [ADDRESS_279987] to clear/almost clear skin 
(PASI  90, IGA mod 2011 0/1) in patients with moderate to severe psoriasis ( defined as ≥10% 
BSA). There was a clear dose response favoring secukinumab 300 mg in the higher thresholds 
of skin clearance. The difference between 300 mg and 150 mg regimens was more 
pronounced in the more difficult -to-achieve PASI 90 and IGA mod 2011 0/1 endpoints, with 
21.9% and 27.4% more patients with ≥ 10% body surface area (BSA) compared to 8.2% and 
3.3% more patients with < 10 % BSA reaching PASI  90 and IGA mod 2011 0/1 responses, 
respectivel y, at Week 24. Therefore, secukinumab 300 mg afforded greater improvement in 
plaque psoriasis than 150 mg, particularly  in the achievement of clear/almost clear skin, in 
patients with moderate to severe psoriasis ( ≥ 10% body  surface area ).
In addition, pertaining to safety  assessment, there were no clinicall y meaningful differences 
among the secukinumab doses of 300 mg and 150 mg in the exposure adjusted incidences 
rates of the key risks over the entire treatment period in the 2 phase III trials in PsA patients. 
The overall safet y in the PsA population was consistent with prior extensive experience in 
psoriasis, and show edthat secukinumab 300 mg and 150 mg are acceptable for chronic use in 
adult patients with active PsA.
[COMPANY_001] Confidential Page 31
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
In study CAIN457F2312 the presence of enthesitis was assessed by [CONTACT_232110]. Overall, the percen tage of patients without resolution of enthesitis atWeek 24 were 
67.6%, 57.8% and 51.8% in the 75 mg , 150 mg and 300 mg s.c. groups, whereas itwas78.5% 
in the placebo group. At Week 24, these differences vs placebo were greater for the 150mg 
and 300 mgdose groups vs placebo (p=0.0108 andp=0.0025, respectively), while 75mg vs 
placebo was simi lar (p=0.17).
Treatment duration: The [ADDRESS_279988] treatment safety  follow -up data in this indication.
3.4 Rationale for choice of comparator
A placebo arm is included in this study  for the duration of the 12 weeks of treatment (7 doses) , 
the placebo group will continue without treatment until week 24. Due to the nature of the 
disease and the primary and secondary  outcome measures used (PROs), a placebo arm is 
necessary  to obtain reliable efficacy  measurements. Adjustment of NSAID dosing is allowed, 
and one local steroid injection ispermitted . 
The regular assessments of disease activity  ensures that subjects experiencing worsening of 
their disease in any  of the treatment groups can exit the study  upon their own wish or based on 
the advice of the investigator at any time. In addition, the inclusion of a placebo group is in 
accordance with health authority  guidelines, including (FDA 1 999; EMA 2 009), and the 
parallel -group, placebo controlled design is in a lignment with Phase II/III trials of other 
biologics in a related therapeutic domain (PsA) as outlined in EMA guidelines ( EMA 2009). 
3.[ADDRESS_279989] one dose if stopped 
due to intolerance to NSAIDs or acetaminophen . Patients should continue on their 
NSAIDs /acetaminophen regimen at time of randomization. The dose of NSAID should
remain stable until the timing of the primary  endpoint at [ADDRESS_279990] 12 weeks 
observation period.
[COMPANY_001] Confidential Page 32
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
3.6 Purpose and timing of interim analy ses/design adaptations
3.[ADDRESS_279991] this benefit, however, they will be followed 
closely  in order to identify  any progress or need for additional therapy .
The risk to subjects in this trial will be minimized by [CONTACT_144941], 
close clinical monitoring and extensive guidance to the investigators, provided in the current 
version of the Investigator’s Brochure (IB).
The risks of secukinumab treatment identified from the clinical experien ce described in 
Section 1.3.1 are:
a)Infections, which are primarily  upper respi[INVESTIGATOR_36115] (non -serious, mild to
moderate in severit y and did not lead to treatment discontinuation) , oral candidiasis, and
other forms of mucosal and cutaneous candidiasis are uncommon
.
b)Neutropenia, mostl y non -serious, transient, spontaneously  reversible, grade 1 -2, seldom
associated with infections and did not lead to treatment discontinuation.
c)
Hypersensitivity ,primarily  non-serious, mild to moderate urticaria, eczema or dermatitis.
The safety  profile of secukinumab remains unchanged since the launch in 2015.
Please refer to the IB for a more detailed review of the pre -clinical and clinical information on 
secukinumab.
Taking into account the individual risks, the expected risk profile of secukinumab from a 
mechanism of action perspective in tendinopathy is anticipated to be similar or less (shorter 
duration of treatment) to that of the approved in dications.
From the standpoint of the overall risk benefit assessment, the current trial with secukinumab 
is justified.
Commercially Confid ential Information
[COMPANY_001] Confidential Page 33
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Women of child bearing potential must be informed that taking the study  treatment may 
involve unknown risks to the fetus if pregnancy  were to occur during the study , and agree that 
in order to participate in the study  they  must adhere to the contraception requirements outlined 
in the Section 4.2 (Exclusion Criteria ). If there is any  question that the subject will not reliabl y 
comply , they  should not be entered or continue in the study .
Risks of imaging procedures
For screening purposes, the patient should have a chest x
-ray that is less than 3month sold. 
Ifthey do not have this(or a historic CT scan or chest MRI) , then a new chest x -ray must be 
performed in the posterior -anterior plane ; the lateral plane is only done if acceptable per local 
practice and regulations. The amount of exposure for a patient chest X-ray is 100 μSv
(https: //www.radiology info.org/en/pdf/safet y-xray.pdf ).
For screening purposes, a shoulder x-raywill be performed in anterior -posterior and lateral 
plane . This is often performed during the routine evaluation of patients with shoulder pain, but 
not alway s. Consequently , in some patients thex-rays may beobtained only for research 
purposes. The total amount of radiation exposure per patient from these X -rays will be about 
100 μSv. The 200 μSvof radiation from both x -rays isequivalent to approximately  28 day s of 
background exposure (approx. 0.3 μSv per hour at sea level). For effective radia tion doses 
under 3 mSv, the risk is considered to be "minimal".
Therefore, the radiation exposure in this study involves minimal risk and is necessary  to
ensure eligibility  of patients. 
The only imaging technique used in this study  for follow -up purposes is MRI
. MRI  is a noninvasive radiology  technique t hat has no x- ray radiation exposure. 
No MRI  contrast agent will be administered in this study . Thus in principle, MRI  scans can be 
repeated in the same patient as often as necessary . The MRI scanning equipment may cause a 
feeling of claustrophobia in susce ptible persons. The presence of metal in the body  may also 
be a safet y hazard or affect a MRI  image quality . For more information, see Section 4.[ADDRESS_279992] a s part of the study . Additional samples may  be required for safet y monitoring.
Timings of blood sample collection are outlined in the Assessment schedule (Section 8.1).
A summary  blood log is provided i
n the Site Operations Manual . Instructions for all sample 
collection, processing, storage and shipment information is also available in the SOM and 
central Laboratory  Manual.
See Section 8.9.5 regarding the potential use of residual samples. 
Commercially Confidential 
Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 34
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
[ADDRESS_279993] 18 years of age, butunder or 
equal to 65 years of age at the time point of randomization with a MRI-positive diagnosis of 
overuse (non -systemic inflammatory ) unilateral shoulder tendinopathy  with sy mptoms present 
for at least [ADDRESS_279994] been refractory  to NSAI Ds and/or acetaminophen as defined in 
the inclusion criteria.  The patients should also have had at least [ADDRESS_279995] be MRI -positive , as indicated by a Sein MRI  tendinopathy  scorin g 
system grade I-III, with no tear or partial tear (maximum 50% tendon thickness = Bauer 
tendon thickness score maximum 2; AP length maximum 10 mm, Bauer tendon length score 
maximum 2. Upto 50% of enrolled patients may have a partial tear. Patients will be strati fied 
to four strata : Patients with or without a tendon tear and patients with or without previous 
local steroid treatment to the affected shoulder .Randomization will occur within these four 
strata.
The investigat or must ensure that all patients being considered for the study  meet the 
following eligibility  criteria. No additional criteria should be applied by [CONTACT_093], in 
order that the stud y population will be representative of all eligible subjects.
Unless specified otherwise in the inclusion/excl usion criteria , subject selection is to be 
established by [CONTACT_232111], except 
for assessment sthat according to theAssessment s chedule are performed at only one of these 
visits. In this case,it is acceptable t o include the patient based on only screening or only 
baseline results. 
A relevant record (e.g.,checklist) of the eligibility  criteria must be stored with the source 
documentation at the study  site.Deviation from any entry  criterion excludes a patient from 
enrollment into the study.
4.[ADDRESS_279996] fulfill all of the following criteria:
1.Written informed consent obtained p rior to all study  specific screening procedures, as 
close to the start of the screening period as possible
2.Male or non- pregnant, non -lactating female patients 18 to 65 y ears of age at 
randomization
3.Presence of unilateral rotator cuff tendinopathy  with:
a.Symptoms present ≥6 weeks, but <12 months prior to randomization
b. Tendinopath y with no more than a 50% tear as established by [CONTACT_232112]
(historic data acceptable if not older than 3 months) and MRI at baseline : Sein MRI  
tendinopathy  scoring s ystem grade I -III; wi th no tear or partial tear [maximum 50% 
tendon thickness (Bauer tendon thickn ess score maximum 2); AP length maximum
10mm (Bauer t endon length score max 2)]. Maximum 50% of patients with partial 
tear
[COMPANY_001] Confidential Page 35
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
c.Pain in the affected s houlder (at rest or on movement) on at least [ADDRESS_279997] week prior to baseline and a score of ≥4 out of 10 on a VAS pain scale  
d. Positive “Painful Arc Test” on examination and/or nightl y pain in the affected 
shoulder on at least [ADDRESS_279998] treatment defined as:
a.NSAID s/ acetaminophen
i. In the run- in period patients should be on a stable dose of NSAIDs and/or 
acetaminophen for atleast 2 weeks prior to randomization , not exceeding –e.g.:
Ibuprofen 1600 mg/d, naproxen 1000 mg, diclofenac 105 mg/d, or diclofenac 
sodium enteric -coated tablets 150 mg/d, or equivalent. 
ii. If patients cannot tolerate these doses, the maximal tolerable do se should be 
used, and may  be augmented with acetaminophen/paracetamol, at doses not 
exceed local guidelines or 4 g/day , whichever is lower. This medication should 
also be at a stable dose for at least [ADDRESS_279999] contraindications to NSAI Dsor to acetaminophen , these 
treatments can be omitted (contraindication, drug and dose must be specified in 
the eCRF).  
iv. Ifpatients were refractory  to at least 2 weeks of previou s treatment as specified 
in 4 i/ii , NSAIDs or acetaminophen treatment can be omitted.
b.Physiotherap y
i. In the run- inand baseline period, patients should have had at least [ADDRESS_280000] be ≥8weeks prior to randomization 
and ≤[ADDRESS_280001] be ≥8 weeks prior to 
randomization
7.Rheumatoid factor (RF) and anti -cyclic citrullinated peptide (anti -CCP) antibodies must 
be negative at Screening
4.2 Exclusion criteria
Patients fulfilling any of the following criteria are noteligible for inclusion in this study . 
Noadditional exclusions may be applied by [CONTACT_093], in order to ensure that the study 
population will be representative of all eligible patients.
1. Use of other investigational drugs at the time of enrollment, or within 5 half- lives of 
enrollment, or within 30 days for small molecules/until the expected PD effect has 
returned to baseline for biologics, whichever is longer; or longer if required by  [CONTACT_13125].
2.History of hypersensitivity  to any  of the study  treatments or excipi[INVESTIGATOR_232093] c hemical classes
3.Rheumatologic , inflammatory  diseases, including but not limited to: PsA,ASand RA
4.Previous shoulder surgery in affected shoulder
[COMPANY_001] Confidential Page 36
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
5.History  of adhesive capsulitis/frozen shoulder or calci fication in the tendon (in affected or 
contralateral shoulder )confirmed by  X-Ray, historic X -Rays can be used if performed 
within 3 month sof baseline
6.Symptomatic osteoarthritis of the shoulder (gleno- humeral , acromioclavicular )(in 
affected or contralateral shoulder confirmed by  X-Ray, historic X- Rays can be used if 
performed within 3 month sof baseline
7.Neck conditions, including but not limited to cervical spi[INVESTIGATOR_232094] , which in the 
opi[INVESTIGATOR_871], may  explain the patient’s sy mptoms
8.Previous platelet rich plasma injections within the last 12 m onths prior to randomization
9.Previous treatment with any  cell-depleting therapi[INVESTIGATOR_90156] -
CD20, investigational agents (e.g. Campath, anti -CD4, anti -CD5, anti -CD3, anti -CD19)
10.Previous exposure to any biologic immunomodulating age nts, including but not limited to 
TNFalpha inhibitors (including, but not limited to adalimumab, infliximab), or biologics 
targeting IL -17 (including, but not limited to secukinumab, ixekizumab or br odalumab) or 
the IL -[ADDRESS_280002] 12 months prior to baseline
11.Patients taking high-potency  opi[INVESTIGATOR_2467], including but not limited to, methadone, 
hydromorphone , and morphine
12.Any intraarticular /subacromial corticosteroid treatment within [ADDRESS_280003] 12 months prior to randomization
13.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a 
female after conception and until the t ermination of gestation, confirmed b y a positive 
human chorionic gonadotropin (hCG) laboratory test.
14.Women of childbearing potential, defined as all women phy siologically  capable of 
becoming pregnant, unless they  are using effective methods of contraceptio n during 
dosing of stud y treatment and minimum [ADDRESS_280004] dose, or longer, if local 
regulations require it (e.g. 20 weeks in EU) . Effective contraception methods include:
a.Total abstinence (when this is in line with the preferred and usual life style of the 
patient. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post-
ovulation methods) and withdrawal are not acceptable methods of contraception
b.Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterect omy), total h ysterectomy  or tubal ligation at least six weeks before taking 
investigational drug. In case of oophorectom y alone, only when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment
c.Male sterilization (at least 6 months prior to screening). For female patients on the 
study , the vasectomized male partner should be the sole partner of that patient
d.Barrier methods of contraception: Condom or occlusive cap (diaphragm or 
cervical/vault caps. For [LOCATION_006]: with spermic idal foam/gel/film/cream/vaginal 
suppository
[COMPANY_001] Confidential Page 37
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
e.Use of oral, (estrogen and progesterone), injected or implanted hormonal methods
of contraception or other forms of hormonal contraception that have comparable
efficacy  (failure rate <1%), for example hormone va ginal ring or transdermal
hormone contraception or placement of an intrauterine device (IUD) or intrauterine
system (IUS)
f.In case of use of oral contraception, women should have been stable on the same
pi[INVESTIGATOR_6522] a minimum of [ADDRESS_280005] 12 months of natural (spontaneous) amenorrhea with an
appropriate clinical profile (e.g. age appropriate, history  of vasomotor sy mptoms)
or have had surgical bilateral oophorectom y (with or without hysterectom y), total
hysterectom y or tubal ligation at least six weeks ago. In the case of oophorectomy
alone, only  when the reproductive status of the woman has been confirmed by
[CONTACT_232113]
15.Chest X -ray, CT or MRI scan with evidence of ongoing infectious or mali gnant process
obtained at screening  or within 3 months prior to screening and evaluated by  a qualified
physician
16.Underl ying metabolic, hematologic, renal, hepatic, pulmonary , neurologic, endocrine,
cardiac, infectious or gastrointestinal conditions which in the opi[INVESTIGATOR_232095] -compromises the patient and/or places the patient at unacceptable risk for
participation in an immunomodulatory  therapy
17. Significant medical problems or diseases, including but not limited to the following:
uncontrolled hy pertension ( ≥160/95 mmHg), congestive heart failure ([LOCATION_001] Heart
Association status of class III or IV) and uncontrolled diabetes
18.Evidence of hypomagnesemia or other reason associated with risk of reduced activity  of
matrix metalloproteinases. Treatment with fluorquinolone antibiotics (mainly
ciprofloxacin, moxifloxac in or similar drugs) associated with risk of mag nesium chelation
and reduced activity  of matr ix metalloproteinases.
19.History  of clinicall y significant liver disease or liver injury  as indicated by  [CONTACT_232114] (LFTs) such as aspartate aminotransferase/serum glutamic oxaloacetic
transaminase (AST/SGOT), alanine aminotransferase/ ser um glutamic py ruvic
transaminase (ALT/SGPT) alkaline phosphatase or serum bilirubin. The investigator
should be guided b y the following criteria:
a. An y single parameter may not exceed 3 x upper limit of normal (ULN). A single
parameter elevated up to and including [ADDRESS_280006] prior to enrollment/randomization, to rule out
any possible lab oratory error
b. If the total bilirubin concentration is increased above [ADDRESS_280007] reacting bilirubin
20.History  of renal trauma, glomerulonephritis, or patients with one kidney  only , or a serum
creatinine level exceeding 1.5 mg/dL (132.6 µmol/L ).
[COMPANY_001] Confidential Page 38
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
21.Screening /baseline total white blood ce ll (WBC) count <3,000/µL , or platelets 
<100,000/µL  or neutrophils <1,500/µL  or hemoglobin <8.5 g/dL (85 g/L).
22.Active s ystemic infections during the last two weeks (exception: common cold) prior to 
randomization.
23.History of ongoing, chronic or recurrent inf ectious disease or evidence of tuberculosis 
infection as defined b y either a positive purified protein derivative ([COMPANY_003]) skin test (the 
size of induration will be measured after 48 -72 hours, and a positive result is defined as an 
induration of ≥ 5mm or according to local practice/guidelines), or a positive Quantiferon 
test. Patients with a positive test may  participate in the study  if further work up (according 
to local practice/guidelines) establishes conclusively  that the patient has no evidence of 
active tuberculosis. If presence of latent tuberculosis is established then treatment 
according to local country  guidelines must have been initiated prior to enrollment.
24.Known infection with human immunodeficiency  virus (HIV) Hepatitis B (HBV) or 
Hepatitis C (HCV) at screening or randomization .  
25.History  of lymphoproliferative disease or any  known malignancy  or history  of malignancy  
of an y organ s ystem(except for basal cell carcinoma or actinic keratoses that have been 
treated with no evidence of recurrence in th e past [ADDRESS_280008] been removed), treated or 
untreated within the past 5 y earsprior to baseline regardless of whether there is evidence 
of local recurrence or metastases .
26.Curre nt severe progressive or uncontrolled disease which in the judgment of the clinical 
investigator renders the patient unsuitable for the trial.
27.Inability  or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability  or lack of access to veins).
28.Any medical or ps ychiatric condition which, in the investigator’s opi[INVESTIGATOR_1649], would preclude 
the participant from adhering to the protocol or completing the stud y per protocol.
29.Donation or loss of [ADDRESS_280009] six months before 
randomization.
31.Plans for administration of live vaccines during the study period or within 6 weeks prior to 
randomization.
32.Inability  or unwillingness to undergo MRI of the shoulder (e.g. ,patients with pacemakers, 
or metal fragments / foreign objects in the body  that are not compatible with performing a 
MRI .
In the case where a safety  laboratory  assessment at screening and/or initial baseline is outside 
ofthe range specified in the exclusion criteria , the assessment may be repeated once prior to 
randomization. If the repeat value remains outside of the specified ranges, the subject must be 
excluded from the study .
Refer to Section 8.3 (Patient Screening ) for information regarding re- screening. 
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study  
population will be representative of all e ligible patients.
[COMPANY_001] Confidential Page 39
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
[ADDRESS_280010] study  treatment administration.
Table 5-1 Prohibited medications
Prohibited treatments Prohibition1
/Washout period before 
randomization2Action to be taken
Any immunomodulating biologic drugs, 
including but not limited to TNFalpha 
inhibitors or other biologic drugs 
targeting IL -17 or IL -17 receptor*Never Discontinue study medication
Any cell -depleting therapi[INVESTIGATOR_232096] -CD20 or 
investigational agents *Never Discontinue study medication
cDMARD (e.g. MTX) including apremilast, 
tofacitinib *Never Discontinue study medication
Any investigational treatment other than 
study medication or participation in any 
interventional trial4 weeks or 5 half -lives 
(whichever is longer)Discontinue study medication
Unstable dose of NSAIDs (including 
selective COX -2 inhibitors) and/or
paracetamol/acetaminophen
[ADDRESS_280011] be recorded
Analgesics other than NSAIDs, 
paracetamol/acetaminophen and low 
strength opi[INVESTIGATOR_232097]2 weeksDiscontinue the forbidden
medication . All medications must be 
recorded
High potency opi[INVESTIGATOR_2438] 12 weeks Discontinue study medication
Systemic corticosteroids 12 months Discontinue study medication
Local steroid injections in the shoulder 
(until Week 14)8 weeks and not more than 3 
injectionsDiscontinue study medication
Intramuscular steroid injection 8 weeks Discontinue study medication
Fluoroquinolone 8 weeks Discontinue study medication
[COMPANY_001] Confidential Page 40
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Prohibited treatments Prohibition1
/Washout period before 
randomization2Action to be taken
Shock wave therapy 8 weeks Discontinue study medication
Live vaccinations 6 weeks Discontinue study medication
Platelet rich plasma injections 12 months Discontinue study medication
Oral or topi[INVESTIGATOR_22775] 12 weeks Discontinue study medication
* These agents fall under the category of biologic immunomodulators and are prohibited medications.
1Never = medication is prohibited from any time point prior to study start and up to and including follow -up visit
2period in weeks refers to washout of prohibited medications during screening counted from randomization visit
Administration of these agent s requ ires study discontinuation.
[ADDRESS_280012] numbering, prescribing/dispensing and taking study  treatment are 
outlined in the SOM.
6.1.1 Investigational and control drug(s)
Table 6-1 Overview of study  medication
Study drug name [CONTACT_232149]
[CONTACT_232115] 300 mg
(2injections of 150 mg)2x 1 mLPFS 1 mL(150 mg) Single - blind supply [COMPANY_001]
Placebo, [ADDRESS_280013] convenient 
for the patient , in agreement with the investigator.
The PFSs are packed in a single blinded fashion and do not need to be prepared. The study 
treatments will be labeled as follows:
Single blind secukinumab and placebo pre-filled sy ringe (PFS)will be labeled AIN457
150 mg/1 ml/Placebo for dosing up to and including Week 12.
For detailed instructions on storage of the investigational treatments, please refer to the SOM.
6.1.2 Additional study  treatment
No additional treatment bey ond investigational drug and control drug are included in this trial.
[COMPANY_001] Confidential Page 41
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
6.2 Treatment arms
Patients will be assigned to one of the following 2 treatment arms in a1:1 ratio, with 
approximately  50 patients per arm. 
Group 1: Secukinumab 300 mg s.c. (2 x 150 mg)
Group 2: Placebo s.c. (2 injections)
Treatment is administered at Day 1 (randomiz ation visit), and Weeks 1, 2, 3, 4, 8 and 12.
Subjects who complete the assessments associated with Week 14visit should continue the 
study  in a ( treatment free )follow up period of [ADDRESS_280014] will be produced by [CONTACT_15017]  (IRT) 
provider using a validated system that automate s the random assignment of subject numbers 
to randomization numbers. These randomization numbers are linked to the different treatment 
arms, which in turn are linked to medication numbers. A separate medication list will be 
produced by [CONTACT_232116] a 
validated system that automates the random assignment of medication numbers to packs 
containing the investigational drug(s).
The randomization number is only used to identify  which treatment the subjects have been 
randomized to receive.  The Subject number assigned to a subject at screening remains the 
unique identifier for the subject throughout the study .  For information on subject numbering, 
please see ‘Subject numbering’ section in the SOM.
Randomizati on will be stratified on the basis of 
Tendinopath y without tear / tendinopath y with partial tear.
Steroid- naïve for the current RC injury  / local steroid treatment for the current RC 
injury .  
The stratification occurs in order to make sure that these two potential factors, which may 
impact response to treatment, are even lydistributed in the treatment groups.
The randomization scheme for subjects will be reviewed and approved by a m ember of the 
Randomization Office.
Follow the details outlined in the SiteOperations Manual regarding the process and timing of 
treatment assignmen t and randomization of subjects.
[COMPANY_001] Confidential Page 42
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
6.[ADDRESS_280015], investigator and sponsor -blinded study . Subjects, investigators and sponsor 
will remain blinded to study  treatm ent throughout the study , except where indicated below. 
The identity  of the treatments will be concealed by [CONTACT_50090], labeling, schedule of administration, appearance, and odor.
Site staff
All site staff (including study  investigator and study  nurse) , except the unblinded pharmacist,
will be blinded to study  treatment throughout the study .
Unblinding a single subject at site for safet y reasons (necessary  for subject management) will 
occur via an emergency  system in place at the site (see Section 6.6 ).
Sponsor staff
All other sponsor staff (study  statistician, study  programmer, biomarker expert, clinical trial 
team, decision boards etc.) will stay blinded to treatment assignments (except in the case of a 
safet y event necessitating unblinding) until after database lock for the analy sis of the primar y 
endpoint at Week 14 .Study  monitors will remain blinded throughout the study .
All unblind ed personnel will otherwise keep randomization lists and data or information that 
could unblind other study  team members confidential and secure until database lock for the 
primary  endpoint at Week 14 . 
Following final database lock all roles may be consid ered unblinded.  See Table 6-2for an 
overview of the blinding/unblinding plan.
The sample analysts will receive a copy of the randomization schedule (via request to the 
Randomization Office), to facilit ate analy sis of the samples. The sample analy sts will provide 
the sample data to the study  team under blinded conditions unless otherwise allowed.
The study  statistician will be able to access the randomization list for interim analyses and is 
allowed to share unblinded information with the rest of the clinical team as appropriate for 
internal decision purposes, as outlined inTable 6-2. For example, unblinded summaries and 
unblinded individual data can be shared w ith the team for after the primary  endpoint analysis 
at Week 14.
Study  programmers and other personnel involved in study  data anal ysis (e.g. biomarker expert) 
are allowed to access treatment assignment information for the purpos e of conducting the 
primary  endpoint anal ysis.
The clinical trial team is allowed to share unblinded results with other sponsor staff 
(e.g. decision boards) as required for internal decision making on the study  or the project at 
the time of interim anal yses while the stu dy is ongoing.
[COMPANY_001] Confidential Page 43
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Table 6-[ADDRESS_280016] generatedTreatment 
allocation & 
dosingSafety event 
(single subject 
unblinded)Primary 
analysis at 
Week 14
Subjects/Patients B B UI B
Site staff B B UI B
Unblinded pharmacist B UI UI UI
Drug Supply and Randomization 
OfficeUI UI UI UI
Statistician/statistical programmer/ 
data analy sts (e.g. biomarker, PK)UI UI UI UI
Unblinded monitor B UI UI UI
All other sponsor staff not 
identified above (trial team, project 
team, management & decision 
boards, support functions)B B UI UI
Key:
UI:Allowed to be unblinded on individual patient level 
B:Remains blinded
NA: Not applicable to this study
6.[ADDRESS_280017] 
convenient for the patient. See the Site Operations Manual for further details.
Sponsor qualified medical personnel will be readily  available to advise on trial related 
medical questions or problems.
6.5.1 Instructions for prescribing and taking study treatment
Study  treatment ([ADDRESS_280018] bo) will be administered by 
[CONTACT_232117] . 
S.c. administration with pre -filled sy ringes
Secu kinumab solution for s.c. injection (150 mg in 1.0 mL  active/placebo) will be provided in 
PFSs. Details of the injection is provided in the SOM. Permitted dose adjustments and 
interruptions of study  treatment
Study  treatment interruption should be avoided with the following exceptions:
[COMPANY_001] Confidential Page 44
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Study  treatment interruption is only  permitted if, in the opi[INVESTIGATOR_871], a subject is 
deemed to be placed at a significant safet y risk unless dosing is temporaril y interrupted. 
Insuch cases study  treatment should be interrupted only during the time that this risk is 
present and ongoing. Study  treatment can be restarted at the next scheduled visit after 
resolution of the safety  risk.
Any study  treatment interruption must be recorded on the corresponding eCRF page.
6.[ADDRESS_280019], he/she must provide 
the requested subject identify ing information and confirm the necessity  to break the treatment 
code for the subject. The investigator will then receive details of the investigational drug 
treatment for the specified subject and a fax or email confirming this information. The sy stem 
will automatically  inform the study  monitor for the site and the Study  Team that the code has 
been broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT at any time in case of emergency .   The investigator will need to 
provide:  
Protocol number
Study drug name (if available)
Subject number. 
In addition, the investigator must provide oral and written information toinform the subject 
how to contact [CONTACT_5657]/her backup in cases of emergency  when he/she is unavailable to ensure that 
un-blinding can be performed at an y time .
6.7 Treatment exposure and compliance
Pharmacokinetic parameters (measures of treatment exposure) will be determined in all 
subjects treated with AIN457, as detailed in Section 8.8 .
Compliance to the treatment regimen is ensured by [CONTACT_232118]457 at the study  
site at all visits as per Assessment schedule except forvisits atweeks 1 and 3, when AIN457
will be administrated by a  nurse at the patients’ home. Information on the study  treatment 
administration or any deviation from the dose regimen must be recorded in the Case Report 
Form (CRF) .  All study  treatment dispensed and returned must be recorded in the Drug 
Accountability  Log.
6.[ADDRESS_280020] be recorded on the Concomitant medications/Significant 
non-drug therapi[INVESTIGATOR_50061].
[COMPANY_001] Confidential Page 45
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
6.[ADDRESS_280021] is experiencing either no benefit from participation in 
the trial or worsening / exacerbation of their disease.
Resc ue medication must not be used before completion of Week [ADDRESS_280022] will be free to discontinue participation 
in the study  at an y time.
Changes in NSAIDs concomitant therap y is permitted after Week 14 assessments as per 
investigator’s clinical judgment.
6.[ADDRESS_280023] to notify  the study  site about any new medications 
he/she takes after the subject has been enrolled into the study . 
All prescrip tion medications, over-the-counter drugs and significant non-drug therapi[INVESTIGATOR_014]
(including physical therapy  and blood transfusions) administered or taken within the 
timeframe defined in the entry criteria prior to the start of the study  and during the study , must 
be recorded on the Concomitant medications/Significant non- drug therapi[INVESTIGATOR_50061].
Medication entries should be specific to trade name, the single dose and unit, the frequenc y 
and route of administration, the start and discontinuation date and the reason f or therap y.
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_232119] a subject 
or, if the subject is already  enrolled, to determine ifthe subject should continue participation 
in the study .
6.10.[ADDRESS_280024] 2 weeks prior to 
randomization until study  Week 14. Please refer for the details in provided separatel y 
Exercise Manual for patients. 
[COMPANY_001] Confidential Page 46
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
[ADDRESS_280025] will be required to complete the study  in its entirety ; no further study  treatmen t 
will be made available after Week [ADDRESS_280026] completes their End of Study  (EoS) visit, 
and any repeat assessments associated with this visit have been documented and followed- up 
appropriatel y by [CONTACT_737], or in the event of an early study  termination decision, the 
date of that decision.
Normally , all randomized and/or treated subjects should have a safety  follow -up call 
conducted [ADDRESS_280027] administration of study  treatment; however the 60days falls 
within the study  12-week follow -up period, where no treatment is given, therefore the safet y 
follow up is part of the Eo S. 
All SAEs reported during this time period must be reported as described in Section [ADDRESS_280028] be discontinued un der the following circumstances:
Subject /guardian decision -subjects may choose to discontinue study  treatment for any 
reason at an y time.
The investigator believes that continuation would negativel y impact the safet y of the 
subject or the risk/benefit ra tio of trial participation.
Emergence of the following adverse events:
-Any severe or serious adverse event that is not compatible with administration of study 
medication, including adverse events that require treatment with an unacceptable co-
medication
-Life-threatening infection
Any protocol deviation that results in a significant risk to the subject’s safety .
Pregnancy  (see Section 8.6 (Safet y)and Section 9.6 (Pregnancy  reporting))
Use of prohibited treatment as per recommendations in Table 5-1.
Adverse events, abnormal laboratory  values or abnormal test results that indicate a safet y 
risk to the subject.
[COMPANY_001] Confidential Page 47
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Any laboratory  abnormalities that in the judgment of the investigator, taking into
consideration the subject’s overall status, prevents the subject from continuing
participation in the study .
The following deviations from the prescribed do se regimen for the st udy drug:
-Missed 2dosesor more
The appropriate personnel from the site and [COMPANY_001] will assess whether investigational drug 
treatment should be discontinued for any subject whose treatment code has been broken 
inadvertentl y for an y reason.
If discontinuation of study  treatment occurs, investigator must determine the primary  reason 
for the subject’s premature discontinuation of study  treatment and record this information on 
the Dosage Administration CRF. 
Subjects who discontinue study  treatm ent or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent (see Section 7.3, Withdraw of Informed Consent ).The patients who discontinue 
the treatment should return to the clinic as soon as possible, after discontinuation of study 
drug, for EoS visit. At a minimum, in abbreviated visits, the following data should be 
collected at clinic visits or via telephone/ email contact: 
New / concomitant treatments
Adverse events/Serious Adverse Events
If they fail to return for the EOS visit
for unknown reasons, every  effort (e.g.,telephone,
e-mail, letter) should be made to contact [CONTACT_423]/pre -designated contact [CONTACT_232120] 7.4 (Lostto follow -up).This contact [CONTACT_37283] y be done according to the
study  visit schedule.
7.[ADDRESS_280029]:
Does not want to participate in the study  anymore and
Does not want an y further visits or assessments and
Does not want an y further study  related contacts and
Does not allow anal ysis of already  obtained biologic material.
In this situation, the investigator must make every  effort (e.g. telephone, e-mail, letter) to 
determine the primary  reason for the subject ’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_5366] -up.
[COMPANY_001] Confidential Page 48
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
7.[ADDRESS_280030] to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator should show "due diligence" by 
[CONTACT_762], e.g. dates of 
telephone calls, registered letters, etc. A subject cannot be formally  considered lost to follow -
up until his/her schedule d end of study visit would have occurred.
7.5 Early study  termination by  [CONTACT_18620]. This may  include reasons 
related to the benefit/risk assessment of participating in the study , practical reasons 
(including slow enrollment), or for regulatory  or medical reasons. Should this be necessary , 
subjects must be seen as soon as possible and treated as a prematurely  discontinued subject. 
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the subject’s interests. 
Theinvestigator will be responsible for informing IRBs/IECs of the early  termination of the 
trial.
[COMPANY_001] Confidential Page 49
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
8 Procedures and assessments
8.1 Assessment schedule
Subjects should be seen for all visits/assessments as outlined in the assessment schedule , Table 8 -1,or as close to the designated day /time as 
possible.
Missed or rescheduled visits should not lead to automatic discontinuation. Subjects who prematurely discontinue the study forany reason 
should be scheduled for a visit as soon as possible, at which time all of the assessments listed for the final visit will be performed. At this 
final visit, all dispensed investigational product should be reconciled, and the adverse event and concomitant medications recorded on the 
CRF.
Table 8-1 Assessment schedule
Epoch Screening Treatment Follow -up
Visit Name [CONTACT_222003]-in2Baseline Treatment Follow -up EOS
Visit Num bers11 2 3 101 102 103 104 105 106 107 199 201 299
Days -49to -22 -21to -8 -7 to -1 1 8 1522
±129
±157
±285
±299
±2127
±7169
±7
Weeks of dosing - - - 0 1 2 3 4 8 12 14 18 24
Informed consent X
Inclusion / Exclusion criteria S S
Medical history/current medical conditions X
Prior medication for tendinopathy X
Hepatitis B, C or HIV serology (only in countries where 
required)S S
Tuberculosis test11S
Demography X
Pregnancy and assessments of fertility3X X X X X X X
Alcohol Test ,Drug Screen S
T3, T4, TSH X
Commer cially Conf idential Information
[COMPANY_001] Confidential Page 50
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Epoch Screening Treatment Follow -up
Visit Name [CONTACT_222003]-in2Baseline Treatment Follow -up EOS
Visit Num bers11 2 3 101 102 103 104 105 106 107 199 201 299
Days -49to -22 -21to -8 -7 to -1 1 8 1522
±129
±157
±285
±299
±2127
±7169
±[ADDRESS_280031] X -Ray7S
Randomization X
Study drug administration4X X X X X X X
Physiotherapy S13S
Physical Examination5S S S
Body Height5X
Body W eight5X X X
Body Temperature5X X X X X X X X X
Blood Pressure and Pulse Rate5X X X X X X X X X
Electrocardiogram (ECG)5S S S S
Hematology5X X X X X
Clinical Chemistry5X X X X X
Urinalysis5X X X X
Lipid panel and glucose5X X
Shoulder X -Ray6, 12S
Shoulder US S
Shoulder MRI X12X X X
Patient pain & NSAIDs diary X
Patient reported outcomes5X X X X X X X X X
Pain VAS X X X
Clinician reported outcome (PhGA)5X X X X X X X X X
Commercially Confidential Information
Commercially Co nfidential Information
Commercially Co nfidential Information
[COMPANY_001] Confidential Page 51
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Epoch Screening Treatment Follow -up
Visit Name [CONTACT_222003]-in2Baseline Treatment Follow -up EOS
Visit Num bers11 2 3 101 102 103 104 105 106 107 199 201 299
Days -49to -22 -21to -8 -7 to -1 1 8 1522
±129
±157
±285
±299
±2127
±7169
±7
Weeks of dosing - - - 0 1 2 3 4 8 12 14 18 24
PD blood (IL -17A)5X X X X
PK blood collection5X X X X
Immunogenicity5X X X
Concomitant medications X
Adverse Events X
Comments X
Study completion information X
1Visit structure given for internal programming purpose only
2Run-in to standardize physiotherapy and stabilize NSAIDS, no site visit required
3Serum pregnancy test required as Screening and EOS, for remaining visits: urine test
4At study day s 8 and 22 study medication can be administered by [CONTACT_232121]
5Collected pre -dose if applicable
6Historic data accepted if obtained ≤ [ADDRESS_280032] X -ray(can be replaced by [CONTACT_232122]) is required if it was not performed and evaluated within [ADDRESS_280033] meets other inclusion/exclu sion criteria in order to minimize unnecessary exposure to radiation. 
8To be done the night before and the night after each visit(except for EOS when it is done only before the visit ).
[ADDRESS_280034] be read within 72 hours and before ra ndomization
12Assessments to be performed maximum 14 days before study Day 1
13 Duration of the standardized physiotherapy might be prolonged if required by [CONTACT_427]
S: collected as source data only
For all subjects who discontinue from the study, the investigator should ensure that the subject completes the end of treatment visit (EOS) [ADDRESS_280035] study 
treatment of secukinumab.  Every attempt should be made to obtain MRI images at the final visit, unless the MRI was taken within 8 weeks before discontinuation.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 52
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
8.2 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC -approved informed consent. 
If applic able, in cases where the patient ’s representative gives consent (if allowed according 
to local requirements), the patient must beinformed about the study  to the extent possible 
given his/her understanding. If the patient is capable of doing so, he/she must indicate assent 
by [CONTACT_37249] y signing and dating the written informed consent document or a separate assent 
form. 
Informed consent must be obtained before conducting any study -specific procedures (e.g. all 
of the procedures described in the protocol). The process of obtaining informed consent must 
be documented in the patient source documents. 
[COMPANY_001] will provide to investigat ors a proposed informed consent form that complies with 
the ICHE6 GCP guideline and regulatory  requirements and is considered appropriate for this 
study . The informed consent form will also include a section related to optional future 
research which will require a separate signature [CONTACT_232150].  
Theprocedures set out in the main consent form concerning the storage, maintenance of 
privacy , and release of the data or specimens for the main study  will also be adhered to for 
any future research. Any changes to the proposed consent form suggested by [CONTACT_232123] b y [COMPANY_001] before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the IB. This informatio n will be included in the patient informed consent and should 
be discussed with the patien t during the study  as needed. Any new information regarding the 
safet y profile of the investigational drug that is identified between IB updates will be 
communicated as appropriate, for example, via an Investigator Notificat ion or an Aggregate 
Safet y Finding. New information might require an update to the informed consent and then 
must be discussed with the subject.
Ensure patients are informed of the contraception requirements outlined in the Section 4.2
(Exclusion criteria).
A copy  of the approved version of all consent forms must be provided to the [COMPANY_001] monitor 
after IRB/IEC approval.
Refer to the SOM for a complete list of I nformed Consent Forms included in this stud y.
Commer cially Confidential Information
[COMPANY_001] Confidential Page 53
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
8.3 Patient screening
It is permissible to re-screen a patien tonce if s/he fails the initial screening; however, each 
case must be discussed and agreed with the Sponsor on a case- by-case basis. 
8.4 Information to be collected on screening failures
Subjects who discontinue from the study  prior to randomization are considered screen failures. 
The reason for not being randomized and demographics will be entered in the CRF. The CRF 
for adverse events (AEs) should be completed for any Serious Adverse Events (SAEs) that 
occurred during the screening period. Adverse events that are not SAEs will be followed by 
[CONTACT_90200]. 
All subjects who have signed informed consent and are randomized into the Treatment Period 
of the study  will have all AEs occurring after informed consent is signed recorded on the 
CRF capturing AEs, and SAEs if applicable, i.e. when SAE criteria are met.
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF whenever in their judgement, the test abnormality  occurred prior to the informed consent 
signature. 
8.5 Patient demographics/other baseline characteristics
Subject demographic and baseline characteristic data to be collected on all patient s and 
recorded in the eCRF include: 
Date of birth, age, sex, race, ethnicit y
Relevant tendinopath yand general medical history/current medical condition data until
the start of study  treatment, such as date of diagnosis o f tendinopathy , previous
tendinopathy therapi[INVESTIGATOR_014], especiall y pain medicatio n and physiotherapy
Potential corticoid steroid treatment and information on potential tear on MRI  will be
recorded to assess patients for eligibility  and to stratify  patients
Whenev er possible, diagnoses and not sy mptoms will be recorded. Further details are outlined
in the SO M.
Investigators have the discretion to record abnormal test findings on the medical history  CRF, 
if in their judgment, the test abnormality  occurred prior to t he informed consent signature.
8.5.1 Hepatitis screen, HIV screen
Hepatitis B and/or hepatitis C and/or HIV serology  testing areto be performed during 
screening period, only if required per local medical practice or local regulations prior to 
initiation of ther apy.
IfHIV test is seropositive , it should beconfirm edby a  second technique available at the 
laboratory  site, e.g., Western blot.  Appropriate counseling will be made available by [CONTACT_232124] a positive finding. Notification of state and federal authorities, as 
required b y law, will be the responsibility of the Investigator.
[COMPANY_001] Confidential Page 54
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Results for Hepatitis and HIV tests will be available as source data at the study  site and will 
notbe recorded within the CRF.
8.5.[ADDRESS_280036] 
3months
.It is recommended that shoulders X-ray is performed in anterior -posterior and 
lateral planes in order to evaluate patient’s eligibility .
8.5.[ADDRESS_280037] eCRF page.
Drugs administered prior to start of treatment and other drugs continuing or started during the 
study  treatment period will be entered in the “Prior/Concomitant medicat ions” or “Significant 
non-drug therapi[INVESTIGATOR_014] ”eCRF page. 
Compliance is expected to be 100%, unless temporary  interruption is needed for safet y 
reasons
. Compliance will also be assessed by a [COMPANY_001] monitor using information provided 
by [CONTACT_110608].
8.6 Efficacy
8.6.1 The PRO efficacy measures, primary  and secondary  objectives:
The impact of tendinopathy  on various aspects of patient’s health-related quality  of life (QoL) 
will be assessed b y the following instruments:
The WORC score
The QuickDASH sco re(in case available in local language/dialect)
The ASES score
The EQ5D -5L score
Patient’s global assessment of disease activity  (VAS)
Patie nt’s assessment of tendinopathy pain intensity  (VAS)
Daily  assessments of pain intensity , as well as any changes in concomitant pain medication
will be recorded in the patient diary .
All questionnaires will be available, in the local languages of the participating countries.
Thepatients will be asked to fill in these PROs at the clinic at the visits specified in the
Assessment schedule .
[COMPANY_001] Confidential Page 55
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Subjects should be given sufficient instruction, space, time and privacy  to complete all study 
PROs. The study  coordinator should check the responses to the questionnaire for 
compl eteness and encourage the subject to complete any missing responses. If subjects 
experience any difficulties with submission after they complete the PROs, the study  staff 
should assist them with submitting their PRO responses. Attempts should be made to collect 
responses to all PROs for all subjects, including patients who prematurely  discontinue prior to 
the study evaluation completion visit. However, if subjects refuse to complete PROs, this 
should be documented in study  source records. Subject’s refusal to complete study  PROs are 
not protocol deviations. 
Guidelines for administering the PRO questionnaires can be found in SOM. 
Completed questionnaires and patient diaries will be reviewed and examined by [CONTACT_1275], before the clinical examination, for responses that may indicate potential AEs or 
SAEs. The investigator should review not only the responses to the questions in the 
questionnaires but also for any unsolicited comments written by [CONTACT_423]. If AEs or SAEs 
are confirmed, then the physician must record the events as per instructions given in 
Section 9.1 and Section 9.2of the protocol. Investigators should not encourage the subjects to 
chan ge the responses reported in the completed questionnaires.
[IP_ADDRESS] The WORC score
The WORC score is a patient reported outcome tool, unique ly developed for the rotator cuff
diseases by[CONTACT_232125]-workers (Kirkley  e t al 2003 ).The WORC is self -administered and 
consists of 21 items divided i nto five domains: Physical Symptoms (6 items); 
Sport/Recreation (4 items); Work Function (4 items); Lifestyle Function (4 items) and 
Emotional Function (3 Items). Items are scored by a [ADDRESS_280038] possible result is 
0 (asymptomatic patient) while the worst possible result is 2100 (highly  symptomatic).
TheWORC Index has a recall period of 1 week and is filled in by [CONTACT_232126] .
Details of the WORC areoutlined in the SOM.  
[IP_ADDRESS] The QuickDA SH score
Quick DASH should be performed in all countries for which local language /dialect is 
available. The Quick DASH is an abbrevia ted form of the DASH a patient reported outcome 
tool, which has been developed by [CONTACT_131547] y of Orthopedic Surgeons along 
with the Institute for Work & Health (Toronto, Ontario, Canada)
(http://www.dash.iwh.on.ca/scoring) . The Quick DASH Index is self-administered and uses 
[ADDRESS_280039] 
disability .It has a  recall period of 1 week . The toolis filled in by [CONTACT_232127] .
Details of the Quick DASH are outlined in the SOM.  
[COMPANY_001] Confidential Page 56
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
[IP_ADDRESS] The A SES score
The ASES score is developed by [CONTACT_232128] y of the American Shoulder and Elbow Surgeons 
for the assessment of shoulder function (Richards et al 1994). The ASES score is 
self-administered and has 17 questions in the a reas of symptoms and functions. The severit y 
of pain is graded on a 10 cm visual analog scale that ranges from 0 (no pain at all) to 10 
(pain as bad as it can be). The recall period is the current point in time . The tool is filled in by  
[CONTACT_232129] .
Details of the ASES are outlined in the SOM.
[IP_ADDRESS] EuroQuol 5 D (EQ- 5D-5L)
The EQ-5D-5L is a wide ly used, self-administered questionnaire designed to assess health 
status in adults. The purpose of the EQ-5D-5L in this study  is to assess the general health 
status of the patients. The measure is divided into two distinct sections. The first section 
includes one item addressing each of five dimensions (mobility , self-care, usual activit y, 
pain/discomfort, and anxiety /depression). Subjects rate each of these items from : 
“noproblem”, “slight problems”, “moderate problems”, “severe problems”, “extreme 
problems /unable " A composite health index is then defined by [CONTACT_232130]. Thesecond section of the questionnaire measures self-rated (global) health status 
utilizing a verticall y oriented VAS where 100 represents the "best possible health state" and 0 
represents the "worst possible health state." Respondents are asked to rate their current health 
by [CONTACT_1299] a mark along this continuum. The recall period is "today," and the questionnaire 
requires approximately  5 to 10 minutes to complete.
The EQ-5D-5L contains six items designed to assess health status in terms of a single index 
value or health utility  score. One of the strengths of the EQ-5D-5L approach is that it allows 
"weighting" by [CONTACT_232131]. 
Published weights are available that allow for the creation of a single summary  health utility  
score. Overall scores range from 0 to 1, with lower scores representing a higher level of 
dysfunction. The EQ5D is filled in by [CONTACT_232132] 1 prior to drug administration and at 
visits specif ied in the Assessment schedule .
Details of the EQ5D are out lined in the SOM.
[IP_ADDRESS] Patient’s assessment of tendinopathy pain intensity and change in 
pain medication
The patient will assess his/her pain in aPRO diary  once per day rating the pain during the 
previous 24 hours. The patient’s assessment of pain will be performed using 100 mm visual 
analog scale (VAS) ranging from “no pain” to “worst possible pain” after the question 
“Please rate the severity of your pain at its worst during the last 24 hours by [CONTACT_40009] X on 
the line below ”.
Similarly , the patient should note down whenever he/she has change dthe 
NSAID/acetaminophen intake .
[COMPANY_001] Confidential Page 57
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
[IP_ADDRESS] Patient’s global assessment of disease activity
The patient’s global assessment of disease activity  will be performed using 100mm VAS 
ranging from ”no activity ” to ”most active ”, after the question "Please indicate with a 
vertical mark ( |) through the horizontal line the global activity of your disease in the last 
24hours ”. 
The patient’s global assessment of disease activity  is filled in by [CONTACT_232132] 1 prior to 
drug administration and at visits specified in the Assessment schedule .
8.6.2 Clinician reported outcome (CRO) efficacy measures collected in the 
trial for secondary  objectives
Physician’s global assessment of disease ac tivity
The physician’s global assessment of disease activity  will be performed using 100mm VAS 
ranging from no disease activity  to maximal disease activity , after the question "Considering 
all the ways the tendinopathy affects your patient, please indicate with a vertical mark ( |) 
through the horizontal line how well his or her condition is today ”. To enhance objectivity , 
the physician must not be aware of the specific patient’s global assessment of disease activity , 
when performing his own assessment on that subject.
The physician’s global assessment of disease activity  is filled in by [CONTACT_232133] 1 
prior to drug administration and at visits specif ied in the Assessment schedule .
8.6.3 Imaging efficacy  measures collected in the trial for secondary  and 
exploratory  objectives are:
[IP_ADDRESS] MRI of the shoulder, Sein score and Bauer score
The MRI Sein score will be used primarily  to grade supraspi[INVESTIGATOR_232098] a modified 4- point scale (Sein e t al 2007), and monitor changes in this grading over 
time as a treatment outcome ( secondary  objective). Tendinopathy  will be characterized by 
[CONTACT_232134] f tendon with increased signal intensity  on all pulse MRI 
sequences, yet not as bright as the fluid on typi[INVESTIGATOR_2855] T2-weighted images. Since tendonisis and 
partial thickness cuff injuries are prevalent in sporting activity  and in middle age, another 
grading system, the Bauer score, will be used as an exploratory  endpoint for a differentiated 
assessment of supraspi[INVESTIGATOR_232099] (Bauer e t al 2014 ). A 9-point 
tendinopathy  grade will be generated out of this approach, i ncluding sub-scores f or tendonisis 
(0-2), tear thickness (0-4) and AP tear size (0-3). Finall y these images will also be used to 
measure thickness of the rotator cuff tendon and assess for presence of bursitis in the area of 
the rotator cuf f.
Enhancement of the subacromial bursa will be assessed. Images will be scored on a scale of 
0–2 depending on the maximum thickness of enhancing tissue: 0: no abnormal enhancement; 
1: up to 3 mm th ickness of enhancing tissue; 2: 3 mm or more enhancing tissue
(Hodgson et al 2012 ).
[COMPANY_001] Confidential Page 58
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
MR images will be acquired at 3T in multiple planes by [CONTACT_232135]/surrou nding tissue separation and adapted to the MRI system 
capabilities. AllMRI  scans will be sent for central reading and allresults obtained post 
Baseline visit will remain blinded to the investigator, patient and sponsor until after the 
primary  endpoint analy sis at week 14. Detailed information can be located in the imaging 
manual. The coded MRI medical images will be used primaril y for analy sis as described in 
this protocol; however, the images may also be used for the development and evaluation of 
new a nalysis methods directly  related to the area of research that this study  covers.
8.7 Safet y
All blood draws and safet y assessments should be done prior to study  treatment 
administration. Appropriate safet y assessments (e.g. evaluation of AEs and SAEs including 
injection site reactions) should be repeated after the dose is administered. Assessments done 
as a part of the safet y evaluation include
:
Evaluation of AE/ SAE’s
Physical examination
Vital signs
Height and weight
Tuberculosis screening: QuantiFERON TB-Gold test or [COMPANY_003] skin test
Chest X -Ray
Electrocardiogram
Local tolerabilit y (Injection site reactions)
Laboratory evaluations (Hematology , Clinical Chemistry , Lipid Panel, Urinaly sis)
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 59
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Pregnancy  and assessment of fertility
Tolerability of secukinumab
Immunogenic ity
8.7.[ADDRESS_280040] in 
sitting position.
Clinically  notable vital sign s are defined in Appendix 1 .
8.7.3 Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing) (both without shoes) will be measured.
If possible, body  weight assessments should be perfor med by [CONTACT_144965] y. 
8.7.[ADDRESS_280041] in the 
supi[INVESTIGATOR_188597] a stable baseline. A single 12 lead ECG iscollected. The Fridericia 
QT correction formula (QTcF) should be used for clinical decisions. The original ECGs 
(onnon-heat-sensitive paper or a certified copy on non- heat sensitive paper), appropriatel y 
signed, must be collected and archived at the study site. The ECG tracing must be labeled 
with study  number, subject initials, subject number, date and time, and filed in the study  site 
source documents. 
Clinically  relevant abnormalities should be recorded on the relevant medical history /Current 
medical conditions eCRF page for the baseline ECG. 
Clinically  relevant abnormalities noted after the baseline ECG should be reported as AE 
(seeSection 9 ).
[COMPANY_001] Confidential Page 60
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
8.7.[ADDRESS_280042] (QuantiFERON TB-Gold) ora locall y 
performed skin test must be performed at the screening visit to screen the subject population 
for latent tuberculosis infection . The results must be known prior to randomization to 
determine the subject’s eligib ility for the stud y. 
Subjects with a positive test may  participate in the study  if further work up (according to local 
practice/guidelines) establishes conclusively  that 
the subject has no evidence of active tuberculosis
if presence of latent tuberculosi s is established then treatment according to local country
guidelines must have been initiated.
Central laboratory  test for Tuberculosis screening
The QuantiFERON TB-Gold test will be analy zed by [CONTACT_2237] . Details on the 
collection, processin g and shipment of samples and reporting of results by [CONTACT_232136].
Local skin test for Tuberculosis screening
A [COMPANY_003] skin test is to be performed at screening and read before randomization to determine 
the subject’s eligibility  for the study .The test dose is bioequivalent to [ADDRESS_280043] super ficial layer under the skin. 
Ifgiven correctl y, the injection should raise a small wheal of about 5 mm, which resolves 
within 10 -15 minutes.
Because the reaction (induration) will take [ADDRESS_280044] return to 
the investigators’ sitewithin that time for a proper evaluation of the injection site. This will 
determine whether the subject has had a significant reaction to the [COMPANY_003] test. A reaction is 
measured in millimeters of induration (hard swelling) at the site. A[COMPANY_003] skin induration 
≥ 5mm (or according to local practice/guidelines
Either a QuantiFERON TB-Gold test ora [COMPANY_003] skin test must be performed at screening. 
Subjects with a positive test may  participate in the study  if further work up (according to local 
practice/guidelines) establishes conclusively  that the subject has no evidence of active 
tuberculosis, or if presence of latent tuberculosis is established then treatment according to 
local country  guide lines must have been initiated.
8.7.6 Ultrasound of the shoulder
Ultrasound of theshoulder is done at screening, in order to assess eligibility  unless US or 
MRI  are available from within previous 3 month and clinical symptoms stabile, these 
examinations can be used for source data. B-mode US is utilized to rule out major structural 
damage to the tendon (i.e. more than 50% tear) or other shoulder pathologies 
[COMPANY_001] Confidential Page 61
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
8.7.[ADDRESS_280045] x-ray(posterior -anterior plane) is required if it was not performed and evaluated 
within [ADDRESS_280046] 
meets inclusion/exclusion criteria in order to minimize unneces sary exposure to radiation. 
TheX-Ray might be replaced by[CONTACT_232137] 3 months prior 
to screening.
8.7.8 Tolerability  of investigational treatments
Tolerability  will be assessed by [CONTACT_20721], laboratory  values, injection site reaction and 
immunogenicit y.The local tolerability  at the site of s.c. injection of the study  treatment will 
be assessed in case of any local reaction, until this has disappeared. The assessment of pain, 
redness, swelling, induration, hemorrhage and itching will be performed by a physician and 
will be recorded on the appropriate CRF capturing AEs, including the severity  (mild, 
moderate, severe) and the duration of the adverse reaction.
8.7.[ADDRESS_280047] be reported and discussed with [COMPANY_001] personnel. The results should be 
evaluated for criteria defining an adverse event and reported as such if the criteria are met. 
Repeated evaluations are mandatory  until normalization of the result(s) or until the change is 
no longer clinicall y relevant. In case of doubt, [COMPANY_001] personnel should be contact[INVESTIGATOR_530].
Clinically  notable laboratory  findings are defined in Appendix 1 .
[IP_ADDRESS] Hematology
Hemoglobin, hematocrit, red blood cell (RBC) count, white blood cell (WBC) count with 
differentials and platelet count will be measured. 
[IP_ADDRESS] Clinical chemistry
Serum chemistries will include sodium, potassium, BUN/ urea, bicarbonate, calcium, 
phosphorous, total protein, calcium, albumin, uric acid, creatinine, CK, total bilirubin, AST 
(SGOT), ALT (SGPT), GGT and alkaline phosphatase ; at all timepoints specified in the 
Assessment schedule . 
If the total bilirubin concentration is increased above 1.[ADDRESS_280048] reacting bilirubin should be differentiated.
Triiodothy ronine (T3), t hyroxine (T4), t hyroid- stimulating hormone (TSH ), 
Rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, and 
interferon -gamma release test done only at screening . FSH is only done at screening and only 
in patients who are reported post- menopausal at screening
[COMPANY_001] Confidential Page 62
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
[IP_ADDRESS] Lipid panel and gluc ose
A lipid profile including High Density  Lipoprotein (HDL), Low Density  Lipoprotein (LDL), 
cholesterol, triglycerides and glucose will be measured from a fasting blood sample.
[IP_ADDRESS] Urinaly sis
Dipstick measurements for protein, blood, and WBC/leukocy tes will be performed at site ad 
documented as source data. 
If dipstick measurement results are positive (abnormal ), results will be captured in the CRF.
Microscopy  must be assessed following an abnormal dipstick test with results captured in the CRF.
8.7.[ADDRESS_280049] not be given to pregnant women; therefore effective methods of birth 
control must be used for women of child- bearing potential (see exclusion criteria definitions,
Section 4.2).
A serum β
-hCG test will be performed in all women at Visit 1 (screening). All women who 
are not surgically sterile at screening will have local urine pregnancy  tests as indicated in
Table 8-1. A positive urine pregnancy  test requires immediate interruption of study  treatment 
until serum β-hCG is performed and found to be negative. If positive, the subject must be 
discontinued from the trial. Additional pregnancy testing might be performed if requested per 
local requirements.  Refer to Section 9.6 for details on Reporting Pregnancy .
Pregnancy testing results are kept in the source data documentation.
Commercially Confidential Info rmation
[COMPANY_001] Confidential Page 63
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Assessments of Fertility
Refer to Section 4.[ADDRESS_280050] also be available as source documentation in the following cases:
Surgical bilateral oophorectomy without a hysterectomy
Reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical
profile.
In the absence of the above medical documentation, FSH testing is required of any female 
subject who states that they are of non-child bearing potential, regardless of reported 
reproductive/menopausal status at screening/baseline
8.7.[ADDRESS_280051] 
screening visit (Visit 1) for anti-CCP antibodies and the 
Rheumatoid Factor (RF)
8.8 Pharmacokinetic s
PK samples will be collected at the timepoints defined in the Assessme ntschedule
(Section 8.1). Follow instructions outlined in the Site Operations Manual regarding sample 
collection, numbering, processing andshipment. See Section 
8.9.[ADDRESS_280052] ing times with Phoenix WinNonlin (Version 6.4 or higher): Cmin .
Commercially Confidential Inf ormation
[COMPANY_001] Confidential Page 64
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
8.9 Other assessments
8.9.3 Immunogenicity  
Blood samples for immunogenicity  (anti-AIN457 antibodies) will be taken pre-dose at the 
scheduled time points as indicated in Table [ADDRESS_280053] discontinues from the study  at any timepoint, he/she will need to
provide a sample at the last visit. The actual sample collection date and exact time will be 
entered on the Immunogenicity Blood collection eCRF. Sampling problems will be noted in 
the Comment section of the eCRF.
A laboratory  manual will be provided to investigators with detailed information on sample 
collection, handling and shipment. Tubes and preprinted labels will be provided by  [CONTACT_232138] 65
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
The detailed methods for immunogenicity  assessment will be described in the Bioanalytical 
Data Report.
Commercially Co nfidential Information
[COMPANY_001] Confidential Page 66
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
9 Safety  monitoring
9.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a subject 
after providing written informed consent for participation in the study until theend of study  
visit. Therefore, an AE may or may not be temporally  or causally  associated with the use of a 
medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the study  treatment are also 
considered an adverse event irrespective if a clinical event has occurred. See Section 9.[ADDRESS_280054] 
one of the following criteria:
They induce clinical signs or sy mptoms,
They are considered clinically significant,
They require therapy .
Clinically  significant abnormal laboratory  values or test results should be identified through a review 
of values outside of normal ranges/clinically  notable ranges, significant changes from baseline or the 
previous visit, or values which are considered to be non-typi[INVESTIGATOR_232100]. 
Investigators have the responsibility  for managing the safet y of individual subject and 
identify ing adverse events. Clinically  notable vital si gns are defined in Appendix 1 .
Adverse events should be recorded on the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, and accompanied by  [CONTACT_6644]:
1.The severity  grade:
Mild: U sually  transient in nature and generally  not interfering with normal activities
Mod
erate: S ufficiently  discomforting to interfere with normal activities
Severe: P revents normal activities
2. Its rela tionship to the study  treatment
Yes or
No
3. Its duration (start and end dates) or if the event is ongoing an outcome of not
recovered/not resolved must be reported.
4. W hether it constitutes a SAE (see Section 9.2 for definition of SAE) and which
seriousness criteria have been met
5. Action taken regarding investigational treatment.
[COMPANY_001] Confidential Page 67
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
All adverse events must be treated appropriately. Treatment may include one or more of 
the following: 
No action taken (e.g. further observation only )
Investigational treatment dosage increased/reduced
Investigational treatment interrupted/withdrawn
Concomitant medication or non- drug therap y given
Hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059] (see Section 9.2 for definition of SAE)
6.its outcome (not recovered/not resolved; recovered/resolved; recovering/ resolving,
recovered/resolved with sequelae; fatal; or unknown).
Information about common side effects alread y known about the investigational drug can be 
found in the IBor will be communicated between IB updates in the form of Investigator 
Notifications.  
Once an adverse event is detected, it must be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the investigational drug, 
the interventions required to treat it, and the outcome.
The investigator must also instruct each subject to report any new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician, believes 
might reasonabl y be related to study  treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to [COMPANY_001].
*Refer to the Site Operations Manual fordata capture methodology  regarding AE collection
for subjects that fail screening.
9.2 Serious adverse event reporting
9.2.1 Definition of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the 
following criteria:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Requires inpatient hospi[INVESTIGATOR_3850], unless
hospi[INVESTIGATOR_062]:
Routine treatment or monitoring of the studied indication, not associated with any
deterioration in condition
[COMPANY_001] Confidential Page 68
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Elective or pre -planned treatment for a pre -existing condition that is unrelate d to the
indication under study and has not worsened since the start of study  drug
Treatment on an emergency  outpatient basis for an event not fulfilling any  of the
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
Social reasons and respi[INVESTIGATOR_37207]’s
general condition
Is medicall y significant, e.g. defined as an event that jeopardizes the subject or may
require medical or surgical intervention.
All malignant neoplasms will be assessed asserious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (please refer toICH
-E2D Guideline 2004).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serio us reactions , such as important medical events that might not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_50068]. 
Examples o f such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_50069] (please refer to ICH-E2D Guideline 2004).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the CRF; SAEs also require individual 
reporting to [COMPANY_001] Chief Medical Office and Patient Safet y (CMO & PS) as per 
Section 9.2.2.
9.2.2 SAE reporting
Information 
about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinicall y 
thorough report. The investigator must assess the relationship of each SAE to study  treatment, 
complete the SAE Report Form in English, and submit the completed form within 24 hours to
[COMPANY_001].
Screen Failures & Run- In Failures
Note the following requirement for Screen Failures: SAEs occurring after the subject has 
provided informed 
consent until the time the subject is deemed a Screen Failure must be 
reported to [COMPANY_001]. 
For subject s considered Run-In Failures, SAEs occurring after the subject has provided 
informed consent until the time the subject is deemed a Run-In Failure must be reported to 
[COMPANY_001].
[COMPANY_001] Confidential Page 69
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Randomized Subjects
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until the last day of study  (which is [ADDRESS_280055] 
administration of study  treatment) must be reported to [COMPANY_001] within [ADDRESS_280056] describe whether the event has resolved or continues, if 
and how it was treated, whether the blind was broken or not (if applicable) and whether the 
subject contin ued or withdrew from study  participation. Each re-occurrence, complication, or 
progression of the original event must be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment a Chief Medical Office 
and Patient Safety  (CMO & PS) Department associate may urgently  require further 
information from the investigator for Health Authority  reporting. [COMPANY_001] may need to issue 
an Investigator Notification (IN) to inform all investigators involved in any study with the 
same stud y treatment that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with EU Guidance 2011/C 172/01 or as per national 
regulatory  requirements in participating countries.
Follow the detailed instructions outlined in the Site Operations Manual regarding the 
submission process for reporting SAEs to [COMPANY_001].   
Note: SAEs must be reported to [COMPANY_001] within 24 hours of the investigator learning of its 
occurrence/receiving follow -up information.
9.[ADDRESS_280057] liver function tests, see Appendix 1 .
[COMPANY_001] Confidential Page 70
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
9.[ADDRESS_280058] s with laborat ory tests 
containing clinically  significant abnormal values (see Appendix 1for notable laboratory 
values) are to be followed until the values return to n ormal ranges or until a valid reason, 
other than treatment related AE, is defined. Standard renal function tests (blood urea nitrogen, 
serum creatinine) will be obtained at regular intervals, but special measures for renal safet y 
monitoring are not planned.
9.5 Reporting of study  treatment errors including m isuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient/subject 
or consumer (EMA definition).
Misuse refers to situation s where the medicinal product is intentionally  and inappropriatel y 
used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  [CONTACT_50104].
Allstudy  treatment errors and uses outside of what is foreseen in the protocol will be 
collected in the dose administration record (DAR) CRF. Study  treatment errors are only to be 
reported to Chief Medical Office and Patient Safety  (CMO & PS) department if the treatment 
error is associated with an SAE. 
All instances of misuse or abuse must be documented in the adverse event (AE) CRF 
irrespective of the misuse/abuse being associated with an AE/SAE. In addition, all instances 
of misuse orabuse must be reported to [COMPANY_001] Chief Medical Office and Patient Safet y 
(CMO & PS). As such, instances of misuse or abuse are also to be reported using the SAE 
form/CRF. Table 9-1 summarizes the repo rting requirements.
Table 9-1 Guidance for capturing study  treatment errors
Treatment error type Document in Dose 
Administration 
(DAR) CRF Document in A E 
CRFComplete SA E form/CRF 
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with an 
SAE
Misuse/Abuse Yes Yes Yes, even if not associated 
with a SAE
For more information on AE and SAE definition and reporting requirements, 
please seeSection 9.1 and Section 9.2 , respectively.
[COMPANY_001] Confidential Page 71
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
9.[ADDRESS_280059] 
be repo rted to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should 
be followed up to determine outcome, including spontaneous or voluntary  termination, details 
of the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or newborn complications. 
Pregnancy  must be recorded on the Pharmacovigilance Pregnancy  Form and reported by [CONTACT_232139] y (CMO & PS) 
Department. Pregnancy  follow -up should be recorded on the same form and should include an 
assessment of the possible relationship to the study treatment. 
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a S AE form.
The study  drug must be discontinued *, though the subject may  stay  in the study , if she wishes 
to do so. All assessments that are considered as a risk during pregnancy  must not be 
performed. The subject may  continue all other protocol assessments. 
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother. 
10 Data revie w and database management
10.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (eCRF) with the 
investigators and their staff. During the study  [COMPANY_001] employs several methods of ensuring 
protocol and GCP compliance and the quality /integrity  of the sites’ data. Themonitor will 
visit the site to check the completeness of subject records, the accuracy  of data capture / data 
entry ,the adherence to the protoc ol and to Good Clinical Practice, the progress of enrollment, 
and ensure that study  drug is being stored, dispensed, and accounted for according to 
specifications. Key  study personnel must be available to assist the monitor during these visits.
Continuous remote monitoring of each site’s data may be performed by [CONTACT_232140]. Additionally , a central anal ytics organization may  anal yze data 
and identify  risks & trends for site operational parameters, and provide reports to [COMPANY_001] 
Clinical Teams to assist with trial oversight.
[COMPANY_001] Confidential Page 72
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject's file. The investigator must also keep the original informed consent form signed by 
[CONTACT_423] (a signed copy  is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards 
require full verification for the presence of informed consent, adherence to the 
inclusion/exclusion criteria, documentation of SAEs, and the recording of data that will be 
used for all primary  and safet y variables. Additional checks of the consistency  of the source 
data with the CRFs are performed according to the study -specific monit oring plan. 
Noinformation in source documents about the identity of the subjects will be disclosed.
10.[ADDRESS_280060] will be defined in the Site Operations Manual and 
Assessment s chedule (Section 8.1) and can be recorded directly  on the CRFs. All other data 
captured f or this study  will have an external originating source (either written or electronic) 
with the CRF not being considered as source.
All data should be recorde d, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
10.[ADDRESS_280061] the data. If the electronic query  system is not used, a paper Data Query 
Form will be faxed to the site. Site personnel will complete and sign the faxed copy  and fax it 
back to CRO working on behalf of [COMPANY_001] who will make the correction to the database. 
Thesigned cop y of the Data Query  Form is kept at the investigator site.
[COMPANY_001] Confidential Page 73
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be proce ssed centrall y and the results will be sent electronically  to 
[COMPANY_001] (or a designated CRO).
Details regarding patient d iary, PRO , and CRO data collection will be provided in SOM .
At the conclusion of the study , the occurrence of any emergency  code breaks will be 
determined after return of all code break reports and unused drug supplies to [COMPANY_001]. 
Theoccurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data analy sis. 
Any changes to the database 
after that time can only be made after written agreement by 
[CONTACT_232141].
10.[ADDRESS_280062] data at the time the trial ends. Any data analysis 
carried out independently  by [CONTACT_232142] s before 
publication or presentation.
11.1 Analysis sets
For all anal ysis sets, subjects will be anal yzed according to the stud y treatment(s) received.
The safety  anal ysis set will include all subjects that received any  study  drug.
The PK analy sis set will include all subjects with at least one available valid (i.e. not flagged 
for exclusion) PK concentration measurement, who received any study drug and with no 
protocol deviations that impact on PK data.
Commercially Confidential Information
[COMPANY_001] Confidential Page 74
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
The PD analysis set will include all subjects with available PD data and no protocol 
deviations with relevant impact on PD data.
11.[ADDRESS_280063].
11.3 Treatments
Data for study  drug administration (rescue medication) and concomitant therapi[INVESTIGATOR_232101].
11.4 Analysis of the primary  variable(s)
The primary aim of this study  is to assess the efficacy  of secukinumab 300 mg s.c. vs. placebo 
in patients with overuse rotator cu ff tendinopathy  in relieving clinical s ymptoms at week 14
11.4.1 Primary  Variable(s)
The primary  variable, the WORC score, will be available at Baseline and weeks 2, 4, 8, 12 
and 14
11.4.2 Statistical model, hypothesis, and method of analy sis
The primary  end-point (chan ge from baseline in WORC score at Week 14) will be analy zed 
by [CONTACT_232143]. Change at 
Week 14 will be compared between treatments to address the primary  objective. The baseline 
WORC score will be included as a covariate. The stratification factors partial tear/no tear and 
previous steroid injection (yes/no) 
will be included in the model as fixed effects. A 95% one-
sided (90% two- sided) confidence interval for the treatment effect at Week [ADDRESS_280064] covariance and a separate mean for each 
treatment and time point will be fitted. These models may  be reduced in number of covarian ce 
and mean parameters b y model comparison using tools such as the BIC criterion for model fit.
11.4.3 Handling of missing values/censoring/discontinuations
Commercially Confidential Information
[COMPANY_001] Confidential Page 75
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
11.4.[ADDRESS_280065], and visit/time and if ranges are 
available abnormalities (and relevant orthostatic changes) will be flagged. Summary  statistics 
will be provided by [CONTACT_10659]/time.
Clinical labor atory  evaluations
All laboratory  data will be listed by [CONTACT_1570], subject, and visit/time and if normal 
ranges are available abnormalities will be flagged. Summary  statistics will be provided by 
[CONTACT_10659]/time.
Adverse events
All informati on obtained on adverse events will be display ed by [CONTACT_50109].
The number and percentage of subjects with adverse events will be tabulated by [CONTACT_50110] a breakdown by [CONTACT_3148]. A subject with multiple adverse eve nts 
within a body  system is only  counted once towards the total of this body  system.
11.4.5 Sensitivity analy ses
Not applicable.
11.5 Analysis of secondary  variable(s)
Secondary  variables include:
Change from baseline in WORC score at weeks 2, 4, 8, 12, 18 and 24
Disability  of Arm, Shoulder and Hand Questionnaire (QuickDASH) score at weeks 2, 4, 8,
12, 14, 18 and 24
American Shoulder and Elbow Surgeons Shoulder Evaluation Form(ASES) score at
weeks 2, 4, 8, 12, 14, 18 and 24
EQ5D score at weeks 2, 4, 8, 12, 14, 18 and 24
Pain score using a VAS scale (considering the last 24 hours) at weeks 2, 4, 8, 12, 14, 18
and 24
Patient global assessment (PGA) score using a VAS scale (considering the last 24 hours),
at weeks 2, 4, 8, 12, 14, 18 and 24
Physician global assessment (PhGA) score using a VAS scale (considering the last
24 hours), at weeks 2, 4, 8, 12, 14, 18 and 24
MRI  Sein score at weeks 8, 14 and 24
Secondary  variables (except Sein score) will be summarized descriptively  and analyses 
similar to the primary  analy sis will be performed.
[COMPANY_001] Confidential Page 76
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
The secondary  endpoint (Sein MRI  score at week 14) will be analyzed by [CONTACT_232144]. A model with an additive treatment effect on the cumulative logistic scale will be 
used, and the common treatment effect estimated andreported together with 90% asymptotic 
two-sided confidence intervals. Baseline SEIN score will be included as a covariate and the 
stratification factors, partial tear/no tear and previous steroid 
injection (yes/no) will be 
included in the model as fixed e ffects.
11.5.1 Efficacy  / Pharmacodynamics
Not Applicable
11.5.[ADDRESS_280066], and visit/time and if ranges are 
available abnormalities (and relevant orthostatic changes) will be flagged. Summary  statistics 
will be provided by [CONTACT_10659]/time.
Clinical laboratory  evaluations
All laboratory  data will be listed by [CONTACT_1570], subject, and visit/time and if normal 
ranges are available abnormalities will be flagged. Summary  statistics will beprovided by 
[CONTACT_10659]/time.
Adverse events
All information obtained on adverse events will be display ed by [CONTACT_50109].
The number and percentage of subjects with adverse events will be tabulated by [CONTACT_50110] a breakdown by [CONTACT_3148]. A subject with multiple adverse events 
within a body  system is only  counted once towards the total of this body  system.
11.5.3 Pharmacokinetics
11.5.4 Pharmacokinetic / pharmacodynamic correlation analy sis
Not Applicable.
Commercially Confidential Information
[COMPANY_001] Confidential Page 77
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
11.5.[ADDRESS_280067] and visit/time.
11.6 Analysis of exploratory  variables
The statistical anal ysis for exploratory  variables will be described in the RAP.
11.7 Sample size calculation
From (de Witte et al 2012 ),one can infer an SD of change in the WORC score from baseline 
to 6 weeks of approximately  22 percentage points. By [CONTACT_232145] a linear 
increase in the change score variability , the 1 4week SD would by  22 multiplied by  [CONTACT_232146] 1.53 (14/6) ; that is, [ADDRESS_280068] size 
of 20/34=0.59. With this effect size, 40 subjects per group completing week 14will provide 
power exceeding 80% to detect a significant difference between treatments by [CONTACT_31806]-sided test 
at significance level 0.05.
11.8 Power for analy sis of key
 secondary  variables
To address the secondary  MRI endpoint (Sein score at Week 14), the sample size of 
40subjects per group completing Week 14will also provide approximately  80% power to 
detect an odds ratio at or above 50%, i.e., that the odds of a Sein score improvement is at least 
50% higher in the treated group than in the placebo group, again by [CONTACT_31806]
-sided test at nominal 
significance level 0.05. This assumes a proportional cumulative odds model as described in 
(Whitehead 1993 ).
Commercially Confidential In formation
[COMPANY_001] Confidential Page 78
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
11.9 Interim analy ses
12 Ethical considerations
12.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC, US Code of Federal 
Regulations Title 21, and Japanese Ministry  of Health, Labor, and Welfare), and with the 
ethical principles laid down in the Declaration of Helsinki.
12.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_50074]/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g. advertisements) and any other written information to be provided to subjects. 
Prior to study  start, the investigator is required to sign a protocol signature [CONTACT_16066]/her agreement to conduct the study  in accorda nce with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality  Assurance representatives, designated 
agents of [COMPANY_001], IRBs/IECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform [COMPANY_001] 
immediately  that this request has been made.
For multi- center trials, a Coordinating Investigat or will be selected by  [CONTACT_232147] a reviewer and signatory  for the clinical study  report. 
Commercially Confidential Information
[COMPANY_001] Confidential Page 79
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
12.3 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report 
the results of this trial will be either submitted for publication and/or posted in a publicl y 
accessible database of clinical trial results.
12.[ADDRESS_280069] Quality  Management (QM) system that includes all activities 
involved in quality  assurance and qualit y control, including the assignment of roles and 
responsibilities, the reporting of results, and the documentation of actions and escalation of 
issues identified during the review of qualit y metrics, incidents, audits and inspections.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed or overseen by 
[CONTACT_232148] (or CRO working on behalf of 
[COMPANY_001]), a group independent from those involved in conducting, monitoring or performing 
quality  control of the clinical trial. The clinical audit process uses a knowledge/risk based 
approach.
Audits are conducted to assess GCP compliance with global and local regulatory  requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes.
[ADDRESS_280070] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and health authorities, where required, it cannot be 
implemented.
13.[ADDRESS_280071] be 
approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC prior to 
implementation. 
Amendments that are intended to eliminate an apparent immediate hazard to subjects may be 
implemented immediately , provided the Health Authorities are subsequently  notified by 
[CONTACT_6670]/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 9 (Safet y Monitoring) must be followed and the Study  Lead 
informed.
[COMPANY_001] Confidential Page 80
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
[ADDRESS_280072] .
Alfredson H, Cook J (2007) A treatment algorithm for managing Achilles tendinopathy : new 
treatment options. Br J Sports Med; 41:211-21 6.
Bauer S, Wang A, Butler R, et al (2014 )Reliability  of a 3T MRI protocol for objective 
grading of supraspi[INVESTIGATOR_232102] s tears. J Orthopaedic Surg Res 9:128 .
Chen XM, Cui L G, He P, et al (2013) Shear wave elastographic characterization of normal
and torn achilles tendons: a pi[INVESTIGATOR_799] . J Ultrasound Med; 32: 449-455.
Coombes BK, Bisset L, Vicenzino B (2010) Efficacy  and safet y of corticosteroid injections 
and other injections for management of tendinop athy: a systematic review of randomis ed 
controlled trials. Lancet; 376:1751 -67.
de Vos RJ, Weir A, van Schie HT, et al (2010) Platelet- rich plasma injection for chronic 
Achilles tendinopath y: a rando mized controlled trial. JAMA; 303:144-9.
de Witte PB, Hen seler JF, Nagels J, et al (2012) The Western Ontario rotator cuff index in 
rotator cuff disease patients: a comprehensive reliability  and responsiveness valid ation study . 
Am J Sports Med; 40: 1611 -9.
EMA guidance document: 
http://www.ema.europa.eu/docs/en_G B/document_library /Scientific_guideline/2009/09/WC5
00003439.pdf
FDA guidance document (1999) : 
www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U C
M071579.pdf
Forde MS, Punnett L and Wegman DH (2005) Prevalence of musculoskeletal disorders in 
union ironworkers. Journal of Occupatio nal and Environmental Hy giene; 2:[ADDRESS_280073] -Pedersen K (2008) Chronic tendinopathy  tissue pathology , pain 
mechanisms, and etiology  with a special focus on inflammation. Scandinavian Journal of 
Medicine & Science in Sports 18, 3-15.
Hodgson RJ, O’Connor PJ, Hensor EMA, et al (2012) Contrast -enhanced MRI  of the 
subdeltoid, subacromial bursa in painful and painless rotator cuff tears. The British Jou rnal of 
Radiology ; 85:1482 -1487. doi: 10.1259/bjr/45423226.
Hume PA, Reid D and Edwards T (2006) Epi[INVESTIGATOR_232103]: epi[INVESTIGATOR_623] , type, 
mechanisms, assessment, management and preventi on. Sports Medicine 36, 151 -170.
ICH E2D (2004) Clinical Safet y Data Management: Definitions and Stan dards for expedited 
reporting. (Internet) Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library /Scientific_guideline/2009/09/WC5
[ZIP_CODE] 807.pdf  Accessed on: 02Dec2016 .
[COMPANY_001] Confidential Page 81
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Kaux JF, Forthomme B, Goff CL, et al (2011) Current opi[INVESTIGATOR_158337] t endinopathy . J Sports Sci 
Med;10: 238-253.
Kirkley  A, Alvarez C and 
Griffin S (2003) The Development and Evaluation of a Disease -
specific Quality -of-Life Questionnaire for Disorders of the Rotator Cuff: The Western Ontario 
Rotator Cuff Index. Clin J Sport Med; 13:84 –92.
Krogh TP, Fredberg U, St engaard -Pedersen K, et al (2013) Treatment of lateral epi[INVESTIGATOR_232104] -
rich plasma, glucocorticoid, or saline: a randomized, double- blind, placebo -
controlled trial. Am J Sports Med 41: 625-35.
Littlewood C, Ashton J, Chance -
Larsen K, et al (2013) Exercise for rotator cuff tendinopathy : 
a systematic review. P hysiotherap y; 98:
101-9.
Maffulli N, Wong J and Almekinders L C (2003) Ty pes and epi[INVESTIGATOR_232105] . 
Clinics in Sports Medicine 22, 675
-692.
McGonagle D and Benjamin M (2009) Entheses, enthesitis and enthesopathy . Reports on 
rheumatic diseases series 6. 4: 1 -6.
Millar NL , Murrell GA, McInnes IB (2017) Inflammatory  mechanisms in tendinopathy  
-
towards t ranslation. Nat Rev Rheumatol;13:110-122.
Mohamadi A, Chan JJ, Claessen FM, et al (201 7) Corticosteroid Injections Give Small and 
Transient Pain Relief in Rotator Cuff Tendinosis: A Meta- analysis. Clin. Orthop. Relat. 
Res.;475: 232-243.
[COMPANY_001] 
Pharmaceuticals Corporation . Cosenty x (secukinumab) injection, for subcutaneous 
use; Cosenty x (se cukinumab) injection, for subcutaneous use. Highlights of prescribing 
information (2016) .
Richards RR, An K- N, Bigliani LU, et al (1994) A standardized metho d for the assessment of 
shoulder function. J Shoulder Elbow Surg; 3:347-352.
Riley  G (2005) Chronic tendon pathology: molecular basis and therapeutic implications. 
Expert Rev Mol Med;7:1 -25.
Riley  G (2008) Tendinopathy --from basic science to treatment. 
NatClin Pract Rheumatol; 
4:82-9.
Scott A and Ashe MC (2006) Common tendinopathies in the upper and lower extremities. 
Current Sports Medicine Reports; 5:
233-241.
Sein ML , Walton J, L inklater J, et al (2007) Reliability  of MRI  assessment of supraspi[INVESTIGATOR_232106] . Br J Sports Med ;41(8):e9 .
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 82
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
Whitehead J(1993) , Sample size calculations for ordered categorical data. Statistics in 
Medicine; 12:2257 -2272.
Commercially Confidential Inf ormation
[COMPANY_001] Confidential Page 83
Amended Protocol Version v02 (Clean ) Protocol No. CAIN457X2201
15 Appendix 1 : Clinically  notable laboratory  values and vital 
signs
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory  tests.
Clinically  notable values will be forwarded to [COMPANY_001]/CRO at the same time that they are 
sent to investigators. Any action based on these laboratory  values should be discussed with 
[COMPANY_001]/CRO personnel .
Table 15-1 Safety  Analyses: Expanded Limits and Notable Criteria
Final Harmonization
Laboratory Variable Notable Criteria
Standard Units SI Units
LIVER FUNCTION A ND RELA TED VA RIABLES
SGOT (AST) > [ADDRESS_280074] > [ADDRESS_280075]
SGPT (ALT) > [ADDRESS_280076] > [ADDRESS_280077]
Bilirubin > [ADDRESS_280078] > [ADDRESS_280079]
Alkaline phosphatase > 2.[ADDRESS_280080] > 2.[ADDRESS_280081]
REN AL FUNCTION, MET ABOLIC AND ELECTROLYTE VA RIABLES
Creatinine (serum) > [ADDRESS_280082] > [ADDRESS_280083]
HEM ATOLOGY VA RIABLES
Hemoglobin 20 g/L decrease from baseline
Platelet Count < 100 x 10E9/L
White blood cell count < 0.[ADDRESS_280084]
Neutrophils < 0.[ADDRESS_280085]